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1

CHAPTER 1
INTRODUCTION
1.

Breast cancer
Breast cancer is the leading type of cancer and the second most common cause

of cancer death in American women [1]. The overall lifetime probability of developing
breast cancer is 1 in 6, and about 1 in 8 women will develop invasive breast cancer in
the United States [2]. According to 2010 estimates, approximately 207,090 new cases
of invasive breast cancer would be diagnosed in women in the United States and about
39,840 women would die from the disease in 2010 [2].
Treatment options for women with breast cancer include surgery, radiation
therapy, chemotherapy, hormone therapy, and targeted therapy. The treatment
decision is made based on the size and location of the tumor in the breast, the results
of lab tests done on the cancer cells, the stage or extent of the disease, and the age
and general condition of the patient [3-7].
Surgery, consisting of lumpectomy (breast-conserving surgery) or mastectomy
(removal of the whole breast), is usually the first line of treatment for breast cancer,
especially early-stage primary breast cancer [7]. However, breast cancer can come
back as a local recurrence (occur in the surgery area), regional recurrence (cancer has
spread beyond the breast), or as a distant recurrence (also known as metastasis)
somewhere else such as lymph nodes, the bones, liver, or lungs within the first two
years if no further treatment is given after surgery [8;9]. Therefore, radiotherapy or
chemotherapy has become an integral part of post-surgical breast cancer management
[3;7]. It has been reported that between 5% and 33% of breast cancer patients develop
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chronic lymphedema after surgery and radiotherapy or chemotherapy, accompanied by
cognitive changes, early menopause, weight gain, hair loss and changes in skin tone
and texture, which all result in significant psychosocial morbidity and decreased quality
of life [10;11]. Thus, patients who prefer to have the best possible quality of life while
they are being treated tend to choose less-aggressive treatments such as hormone
therapy and targeted therapy.
Hormonal therapies, including selective estrogen receptor modulators (SERMs),
aromatase inhibitors and estrogen receptor down-regulators (ERDs), are used
to prevent early-stage, hormone receptor-positive breast cancer recurrence after
surgery and to treat advanced-stage/metastatic hormone-receptor-positive breast
cancer in both pre- and post-menopausal patients [12]. Targeted cancer therapies
recognize and block specific characteristics of cancer cells and simultaneously activate
defense responses. Therefore, targeted therapies are generally less likely than
chemotherapy to harm normal, healthy cells. Moreover, novel conjugates of antibodies
with cytotoxic agents that are activated after entering the cancer cell are under
investigation [13].
Although these two kinds of less-aggressive treatment are widely used, hormone
therapies primarily target estrogen receptor (ER)-positive breast cancer, and the
majority of targeted therapies work specifically against HER2-positive breast cancer
[12;13]. Neither of these approaches is effective against triple-negative breast cancers
(TNBC) (ER-, progesterone receptor (PR)-, and HER2-negative). TNBC has become a
focus of intense research because TNBC patients present at a younger age at onset
and have a higher tumor grade, larger tumor size, and increased propensity to develop
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metastases. Most importantly, they lack the three most significant therapeutic markers
for clinical management resulting in the worst outcome when compared with other
cancer subtypes, which motivates the investigation of novel approaches for the
prevention and treatment of this aggressive form of breast cancer [14-18]. Another
major clinical problem is that the majority of tumors will eventually manifest resistance
during the course of hormone and targeted therapies [19-21]. Therefore, it is critical to
identify new therapeutic targets both to improve the prognosis and survival rate of
patients with all forms of breast cancer and to prevent breast cancer from developing by
identifying women at increased risk and intervening to modify risk.
2.

Estrogen and breast cancer
Based on the results of clinical and epidemiological studies, the well-established

risk factors for breast cancer have been summarized as earlier age at menarche,
nulliparity, later age at first full-term birth, later age at menopause, history of breast
cancer in a first-degree relative, and socioeconomic status [22-26]. The majority of
these risk factors indicate that prolonged cumulative exposure to endogenous estrogen
may increase the risk of developing breast cancer [27;28]. The estrogen-sensitive
nature of breast cancer has also been implicated by the fact that surgical removal of
ovaries significantly reduces breast cancer risk in pre-menopausal women [29;30].
About 95% of breast cancer is initially hormone-dependent, which also indicates the
crucial role of estrogen in breast cancer development and progression [31;32].
2.1 Critical estrogen exposure periods
Emerging evidence supports the hypothesis that there are critical periods during
a woman's lifetime during which estrogen exposure increases breast cancer. The
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intrauterine period, adolescence and full-term pregnancy are intervals in which
mammary tissue undergoes a high rate of proliferation and extensive differentiation.
Therefore, a high level and/or prolonged duration of estrogen exposure during these
vulnerable periods may dramatically increase the risk of breast cancer.
Data from animal and human population studies provide leads to the critical role
of estrogen exposure in uterus on one‟s risk for breast cancer development later in life.
During pregnancy, the levels of intrauterine estrogen are at least 10 times higher than
they are in women who are not pregnant, and the levels gradually increase throughout
pregnancy [33-35]. The hypothesis that factors positively associated with intrauterine
estrogen exposure such as gestational age, birth weight and birth length, are positively
associated with breast cancer risk has been extensively investigated. Examples of
findings from these studies are the following:


Longer gestation is an indicator of prolonged exposure to pregnancy hormones
and has been postulated to be associated with increased breast cancer risk.
However, epidemiology studies have not provided consistent supportive results.
Two matched case-control studies done in either women aged 14-37 years or
who were twin births support a role for early estrogen exposure in the
development of breast cancer [36;37]. However, three other cohort studies
indicate an inverse relationship between gestational age and breast cancer risk
[38-40].



Increased birth weight and length have been demonstrated to be positively
associated with prolonged in utero estrogen and other maternal hormone
exposure [41-44]. Studies to date have generally suggested a positive correlation
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between birth weight and length and breast cancer risk, especially in premenopausal breast cancer cases [36;38;45-48]. A nested case-control study
within the cohorts of two Nurses‟ Health Studies indicates that pre-menopausal
breast cancer risk is significantly associated with increased birth weight [46]. This
finding is consistent with that reported in another British cohort study of 2167
women (including 59 breast cancer cases, 21 of which were diagnosed before
menopause), in which women who had high birth weight were five times (relative
risk=5.03; 95% confidence interval=1.13, 22.5) more likely to develop
premenopausal breast cancer than were women who had low birth weight (Pvalue for linear trend=0.03) [48]. A record linkage study of 373 Norwegian breast
cancer cases and 1150 age-matched control women provided strong evidence
that breast cancer risk was positively associated with both birth weight and birth
length (P for trend=0.02) [47]. The same author conducted another prospective
population-based study in a cohort of 16,016 women in Norway (including 312
breast cancer cases) and reported a similar positive association between birth
weight and length and breast cancer risk [45].
Animal studies also provide evidence that intrauterine factors influence future
breast cancer risk [49]. Increased levels of estrogen due to high dietary fat intake in
pregnant rats enhanced mammary tumor development in first-generation female
offspring [49;50]. Similarly, a later study provided evidence that the plasma estrogen
levels of pregnant rats were significantly elevated by feeding them a diet high in n-6
polyunsaturated fats. This finding indicated that the female offspring of high-fat-fed rats
were more vulnerable to carcinogen treatment, as manifested by significantly higher
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mammary tumor incidence and shorter latency, than were the offspring of pregnant rats
fed a low-fat diet [50].
In addition to those studies demonstrating that increased exposure to estrogen in
utero can result in increased breast cancer development during adulthood, two studies
have demonstrated that offspring of women with preeclampsia, a pregnancy-induced
condition characterized by decreased levels of pregnancy hormones [51;52], have a
significantly lower breast cancer risk [40;53].
In summary, all of the findings described above suggest that prolonged exposure
to estrogen and other hormonal factors particularly in utero may initiate the carcinogenic
process in mammary gland tissue and affect breast cancer risk later in life.
The most dramatic development of breast tissue occurs during puberty when the
ovaries begin to secrete estrogen and other hormones [54;55]. Therefore, breast
tissue is most vulnerable to carcinogen exposure during this period. Breast cancer risk
is closely related to the duration of estrogen exposure that is estimated by the ages of
menarche and menopause. It has been estimated that breast cancer risk is reduced by
4 to 20% each year that menarche is delayed [56;57]. Similarly, epidemiology studies
indicate a 1.5-fold increase in breast cancer risk for women who have an early age of
menarche [58]. Another factor that can be translated into high estrogen exposure is
body mass index (BMI). However, BMI is not always positively associated with breast
cancer, and its association with breast cancer varies by menopause status. Numerous
case-control studies and cohort studies suggest that BMI is nonlinearly inversely
associated with breast cancer risk in pre-menopausal women, but nonlinearly positively
associated with post-menopausal breast cancer risk [59-65]. Some of these studies
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indicate that one‟s BMI at puberty is closely associated with breast cancer risk in adult
life [61-65]. In a cohort study of 117,415 women (including 3340 cases of breast
cancer), BMI at 14 years of age was inversely associated with increased breast cancer
development during adulthood [65]. Four other studies also support this finding [61-64].
It has been suggested that pregnancy and lactation, especially the first full-term
pregnancy, completes the full differentiation of breast tissue [66]. Therefore, the breast
is highly susceptible to the influence of carcinogen during this period. Early age of first
and second full-term pregnancy and the number of births have been associated with a
long-term reduction in breast cancer risk, especially for postmenopausal women,
according to a large scale study including 1.7 million Norwegian women born in the
period 1925 to 1979 (including 22,890 breast cancer cases at ages 20–74 years) [67].
Two epidemiological studies showed that prolonged breastfeeding was associated with
an additional protective effect against breast cancer development in premenopausal
women [68;69]. In addition to the repeatedly demonstrated protective effect of early
first pregnancy and breast-feeding in epidemiological studies, experiments in rodent
breast cancer models have also confirmed the inverse association between age at first
pregnancy and breast cancer risk [70-73]. The protective role of reproduction in the
susceptibility to carcinogen-induced breast cancer is demonstrated by the finding that
nulliparous rats are highly susceptible to the induction of mammary carcinomas by
carcinogen 7,12-dimethyl benzanthracene [70-72]. Similarly, the study of Yang et al
[73] also supports the protective role of parity and lactation against N-methyl-Nnitrosourea treatment induced mammary carcinogenesis.
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Therefore, understanding the biology of estrogen in greater depth will facilitate
the development of new interventions for breast cancer prevention and treatment.
2.2 Estrogen biosynthesis
The naturally occurring estrogens, 17β-estradiol (E2), estrone (E1), and estriol
(E3), are C18 steroids derived from cholesterol, among which E2 is the predominant
endogenous activator of ER-mediated cellular processes [19]. In premenopausal
women, the primary source of estrogen is E2 produced by the ovaries with
concentrations that fluctuate during menstrual cycles from 40 to 250 pg/ml [74].
However, in postmenopausal women, the serum E2 concentration is often lower than
20 pg/ml and E1 becomes the predominant form of estrogen [74]. Adipose tissue is
another important

source of estrogen, particularly in pre-pubertal girls and

postmenopausal women [75].
Although circulating estrogen levels are decreased by 90% in postmenopausal
women,

the majority of breast carcinomas arise after menopause and the intra

tumoral concentration of E2 is more than 10 times higher than in plasma [74;76-79].
Previous investigations also demonstrated that a large proportion (around 75% in
premenopausal women and almost 100% in postmenopausal women) of the bioavailable estrogen is derived from de novo biosynthesis in peripheral tissues. Overall,
this finding highlights the importance of in situ metabolism of estrogen in cancer target
tissues [80-83]. In the breast, three main pathways are involved in the in situ formation
of estrogen [84-86]:


Aromatase (CYP19) pathway: CYP19 catalyzes the rate-limiting step in the
conversion of androstenedione taken up by the tumor from the blood into E1, which
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is then converted into E2 by 17-β hydroxysteroid dehydrogenase type 1 (17-β
HSD1) [87-89]. It has been demonstrated that in situ metabolism of estrogen
through the CYP19 pathway is correlated with the risk of developing breast cancer
[22;90]. CYP19 expression is significantly increased in breast carcinoma compared
to nonmalignant breast tissue, and its expression also increases during breast
cancer malignant progression, with the highest level in invasive breast carcinoma,
which supports the therapeutic potential of targeting the CYP19 enzyme for breast
cancer treatment [91].


17β-HSD pathway: The enzymes of the 17β-HSD gene family are responsible for
the interconversion of dehydroepiandrosterone (DHEA) and testosterone and of E1
and E2, which indicates that this enzymatic activity is required for the synthesis of all
androgens and estrogens [18]. The distribution and activity of estrogenic 17β-HSD
has been studied in 15 human tissues. Estrogenic 17β-HSD activity was detected in
all tissues examined with the highest rates in placenta, liver, ovary, endometrium,
testis and adipose tissue [92]. The mRNA levels of 17β-HSD1, which catalyzes the
reduction of E1 to E2, was significantly higher in breast cancer lesions from
postmenopausal patients than that in tumor from premenopausal patients, and the
protein expression of this enzyme was detected in about 60% of breast carcinomas,
which correlated with ER and PR levels [78;93]. 17β-HSD activity was significantly
higher in tumoral tissues than in the normal surrounding mammary tissue [78;94;95].



Sulfatase pathway: Steroid sulfatase (STS) converts estrone sulfate taken up by
the tumor from the blood into E1, and then 17β-HSD1 converts E1 into E2. STS
expression was detected in approximately 70% of breast carcinoma cases and was
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higher in breast carcinoma lesions than in the surrounding normal tissue [96-99].
STS expression correlates with an increased risk of breast cancer recurrence, poor
clinical outcome, and a significantly shorter relapse-free survival in breast cancer
patients, which emphasizes the importance of sulfatase-mediated local production
of estrogen in the malignant progression of breast carcinomas [96-99].
2.3 Estrogen carcinogenesis in breast cancer
Carcinogenesis is a multistage process that includes initiation and promotion
[100-102]. The initiation of carcinogenesis is an irreversible, direct increase in
chromosomal aberrations and mutation of oncogenes and tumor suppressor genes
[100-102]. Promotion is an interruptible or reversible stage during which the initiated
cells undergo clonal expansion [100-102]. It has been suggested that estrogens are
unique carcinogens affecting both tumor initiation and promotion. There are mainly two
mechanistic explanations for the involvement of estrogen in breast cancer processes.
The classical, well accepted mechanism for the role of estrogen in breast
carcinogenesis is that estrogens stimulates cell growth, increases the rate of cell
division and suppresses apoptosis, which can enhance opportunities for DNA mutation
and render a spontaneous or chemically-induced mutation permanent [103-107]. These
actions of estrogen can be achieved through pathways mediated by ER.
There are two ER subtypes, ERα and ERβ, which have different estrogen
affinities, expression patterns and responses to ER modulators and anti-estrogens
[108-110]. For instance, E1 and E2 have a higher affinity for ERα, while some
phytoestrogens bind with higher affinity to ERβ [110]. Endothelial cells, bone and kidney
express mainly ERβ, while breast cancer cells and ovarian stroma contain mostly ERα
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[109]. Moreover, ERα and ERβ mediate different transcriptional effects due to the
distinctive conformations of their major transactivation domains [111;112]. For example,
E2 might activate transcription when it binds to ERα but display the opposite effect
when it binds to ERβ [113]. Therefore, the effects of estrogens may vary in different
tissues and cells, and may even be different in the same cell at different time points due
to the structure of the hormone, the subtype of ER involved, the characteristics of the
target gene promoter, and the availability of coactivators and corepressors.
ERs are mainly functional as ligand-dependent transcription factors [19].
Estrogens readily diffuse across the cell membrane and interact with ERs in the nucleus
where the homodimeric complexes bind to estrogen response elements (EREs) and
recruit coactivators or corepressors to regulate the transcription of estrogen-responsive
genes involved in cell proliferation and cell survival [19]. However, recently it has been
reported that one-third of estrogen regulated-genes do not contain conserved EREs in
their promoter regions [114]. This finding led to the investigation of ERE-independent
transcriptional activation by estrogen-ER complexes. In this circumstance, ER binds to
alternative regulatory DNA sequences such as AP-1, SP-1, cyclic AMP (cAMP)response element, and upstream stimulatory factor sites, or acts as a coactivator by
interacting with other DNA-bound transcription factors, such as c-jun or c-fos proteins,
to stabilize the DNA binding of the transcription factor complex or recruit other
coactivators to the complex [115-117]. The expression of a variety of proteins involved
in cell proliferation and metastasis, such as insulin-like growth factor receptor 1, cyclin
D1, c-myc, collagenase, and the anti-apoptosis factor Bcl-2, are regulated in this
manner [116;118-120]. Interruption of ERE-independent transcriptional activation,
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especially at the AP-1 site, results in the in vivo and in vitro resistance of breast cancer
cells to growth stimulation by estrogen or other growth factors, which indicates that
these alternative ER signaling pathways may play an important role in estrogenmediated breast cancer development and progression [121].
In addition to the above mentioned estrogen-dependent transcriptional
activation, several kinases in the growth factor signaling networks, including mitogenactivated kinases (MAPK), Akt, p90 ribosomal S6 kinase (p90RSK), protein kinase A
and c-Src, can also activate ER signaling through an estrogen-independent mechanism
[122;123]. These kinases can directly phosphorylate several sites of ER such as
S104/106, S118, S167, T331 and Y153 [124-130]. For example, both the PI3k-Akt and
MAPK pathways can enhance transcriptional activation of ER by phosphorylating ER at
serine 167 [124-126]. Additionally, the MAPK pathway can also activate cell
proliferation and transform cells by phosphorylating ER at serine 118 [127-130].
Furthermore, these kinases can also indirectly stimulate ERα transcriptional activity by
phosphorylating either coactivators for ERα, such as the p160 family coactivator AIB1,
or other kinases, such as P90RSK, which can then phosphorylate ER [124;131;132].
These genomic signaling pathways take hours to days to alter responsive genes
and produce effects on cells. However, there are some rapid responses to estrogen
simulation that occur in minutes, which can not be accounted for by changes in gene
expression mediated by nuclear ERs. These rapid responses include the generation of
second messengers, such as cAMP, Ca2+, and nitric oxide, as well as the activation of
various receptor tyrosine kinase and protein lipid kinase pathways, such as the MAPK
signaling pathway, which will affect cell adhesion, migration, survival and proliferation
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[133-139]. These non-genomic effects of estrogen are mediated through a membranebound form of ERα, ERβ, or both, and its cross-talk with other signal transduction
pathways, such as epidermal growth factor (EGF) receptor and insulin-like growth factor
receptor-signaling pathways [133;134;140-144]. Alternatively, estrogens might act
through non-ER-mediated pathways [145].
In addition to ERs, recent studies indicate that rapid effects of estrogen are also
mediated by a novel transmembrane G protein-coupled receptor 30 (GPR30), also
known as G protein-coupled ER, based on correlations of receptor expression with
estrogen-mediated Erk-1/2 activation, association of receptor with local ER expression
in breast cancer cell lines, and cellular estrogen binding [146-148]. GPR30 is also
reported to mediate a c-fos–related, ERE-independent genomic signaling pathway of
estrogen [149]. In support of the role of GPR30 in mediating estrogen signal
transduction, several studies report that estrogen can bind to GPR30 with high affinity
[148;150]. The activated GPR30 can then initiate intracellular second messenger
signaling pathways and activate Src, which is involved in matrix metalloproteinase
activation and heparin-binding EGF-like factor (HB-EGF) release [151;152]. Free HBEGF can bind EGF receptor and activate multiple downstream events, such as (1)
activation of phospholipase C that can produce inositol trisphosphate (IP3) to mobilize
calcium; (2) activation of phosphoinositide 3-kinases and its downstream AKT pathway;
and (3) activation of MAPK that can lead to the activation of numerous cytosolic
pathways and nuclear proteins [151-154]. These findings indicate that GPR30 is
involved in the regulation of cell proliferation, invasion, metastasis and target gene
expression. Furthermore, decreased expression of GPR30 in human breast cancer and
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the strong inverse association of GPR30 with cancer cell proliferation, migration,
invasion, metastasis, differentiation and progression have been reported [149;155-166].
In addition, approximately half of classic ER negative breast tumors retain GPR30
expression, which indicates that these tumors (GPR30+/ER-) may remain responsive to
estrogen-targeted treatment through the GPR30 signaling pathway [164]. Therefore,
these important roles of GPR30 in estrogen-induced signal transduction and the strong
association between GPR30 and breast cancer development and progression indicate
that GPR30 may be a novel therapeutic target for breast cancer treatment, especially
for ER negative breast cancer patients.
Another theory that can explain the involvement of estrogens in breast
carcinogenesis is that reactive metabolites of estrogens, especially estrogen catechols
and estrogen quinones, can directly induce mutations [167-175]. Enzymes that are
involved in estrogen carcinogenic metabolism will be discussed in detail in the following
sections.
2.4 Estrogen genotoxic metabolite metabolism
Once formed, estrogens are subjected to extensive local metabolism, such as
oxidative and conjugation reactions, that can lead to either their deactivation and
subsequent elimination or to the generation of genotoxic metabolites [176-178].
Therefore, further estrogen metabolism after biosynthesis is of great importance for
both determining the estrogen levels in breast tissue and breast carcinogenesis. The
main types of metabolic reactions include oxidation by cytochromes P450 (CYPs), Omethylation by catechol O-methyltransferase (COMT), glucuronidation by UDPglucuronosyl transferases (UGTs), and sulfonation by sulfotransferases (SULTs).
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Oxidation: Endogenous estrogens undergo oxidative metabolism catalyzed by
various CYP enzymes in both liver and estrogen target organs (e.g., breast). (Fig. 1.1).
However, since liver and estrogen target organs express different CYP enzymes, it is
necessary to consider the specific CYPs that are expressed in human mammary tissue
when considering the role of CYP-mediated metabolism in local estrogen regulation
[176;179-182].
CYP1B1 is over-expressed in many kinds of tumors relative to normal tissues
[183-186]. CYP1A1 is an inducible enzyme that has high catalytic activity for 2hydroxylation (2-OH) of E2 and E1, while CYP1B1 has a distinct, selective activity for
the 4-hydroxylation (4-OH) of E2 and E1 [187]. Because the expression level of
CYP1B1 is higher than CYP1A1, 4-hydroxylation is the dominant pathway of E2
oxidation in human breast and uterus [188;189].
CYP enzymes also catalyze the further oxidation of the 2-OH and 4-OH catechol
estrogens (2-OHE and 4-OHE) to reactive semiquinones and quinones that can directly
form several types of DNA adduct [190-192]. Moreover, both catechol estrogens and
their quinone/semiquinone metabolites can indirectly damage DNA and protein through
redox cycling and generation of reactive oxygen species (ROS) [193-195]. Therefore,
CYP-mediated estrogen metabolism can lead to the formation of both oxidative DNA
damage and estrogen DNA adducts, which implies that these estrogen metabolites are
potential initiators of tumor formation.
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Fig. 1.1 Pathways of oxidative estrogen metabolism. CYP1B1
catalyzes the oxidation of E2 to catechol estrogen 2-OHE2 and
4-OHE2. The catechol estrogens are further oxidized to
semiquinones (E2-2,3-SQ and E2-3,4-SQ) and quinones (E22,3-Q and E2-3,4-Q). GSTP1 catalyzes the conjugation of GSH
to the estrogen quinones, leading to the formation of 2-OHE24-SG,
2-OHE2-1-SG,
and
4-OHE2-2-SG.
CYP1B1
preferentially forms 4-OHE2, and GSTP1 favors the formation
of 4-OHE2-2-SG and 2-OHE2-4-SG as indicated by the larger
arrows. (Figure from Hachey D L et al. Cancer Res 2003;
63:8492-8499)
Experiments on cell transformation, mutagenicity and carcinogenesis have
suggested that 4-OHE2 is more carcinogenic than 2-OHE2 [193;196-200;200-202]. It
has been found that 4-OHE2 is a stronger ER agonist than the parental E2, which
makes this metabolite a potent promoter of tumor formation [203]. Elevated levels of 4OH-estrogens have been measured in breast adenocarcinomas [204]. Treatment with
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4-OHE2 enhanced adrenal tumor formation in the Syrian hamster [193;200], and
neonatal exposure to E2, 2-OHE2, and 4-OHE2 induced endometrial carcinomas in 7,
12, and 66%, respectively, of treated CD-1 mice [202]. 4-OHE2 was reported to
increase the production of free radicals that cause subsequent hydroxyl radicalmediated damage to DNA, whereas 2-OHE2 failed to induce oxidative DNA damage,
possibly due to rapid methylation by COMT [200;201]. A higher 4-OHE2:2-OHE2 ratio
has been detected in benign and malignant mammary tumors than in adjacent normal
tissue [198;199]. The 2-hydroxylated estrogen metabolites, when compared with 4OHE2, have a faster rate of metabolism by COMT, a more rapid clearance in vivo, and
possess weaker hormonal potency in estrogen target tissues [205-210]. Moreover, 2OHE2 and its methylated metabolite, 2-methoxyestradiol, have actually been shown to
inhibit breast cancer growth and angiogenesis, both in vivo and in vitro, which may be
an

important

reason

for

the

lack

of

carcinogenicity

of

2-OHE2.

[196;196;197;197;211;212]. Therefore, all of these findings indicate that 4-OHE2 and
CYP1B1, the main enzyme that catalyzes the formation of 4-OHE2, play an important
role in breast carcinogenesis.
O-methylation: The O-methylation of catechol estrogens is catalyzed by COMT,
an S-adenosylmethionine-dependent methyltransferase enzyme [213]. The COMT
gene is located on chromosome 22q11 and this enzyme exists in two forms, soluble
cytosolic COMT, which is the main form of COMT, and membrane-bound COMT
[213;214]. Recently, COMT has been closely associated with breast cancer. COMT
inactivates catechol estrogens, the most carcinogenic and genotoxic estrogen
metabolites, and therefore prevents both direct DNA damage and oxidative genomic
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alterations [190-195]. The monomethylated estrogen metabolites have essentially no
ER binding affinity, which suggests that COMT mediated O-methylation is a
detoxification pathway for these catechol intermediates [215;216]. The methylated
product of 2-OHE2, 2- methoxyestradiol, inhibits the proliferation of several cancer cell
lines and is among the most potent endogenous inhibitors of angiogenesis, indicating
that COMT may play a protective role against estrogen-induced breast cancer
[196;197;217;218].
Glucuronidation: The superfamily of microsomal UGT enzymes catalyzes the
conjugation of UDP-glucuronic acid to various endogenous and exogenous aglycones,
including estrogen [219]. Steroid hormone glucuronidation has been identified in
several human organs including the breast [220;221]. Glucuronide conjugates of
estrogens and catechol estrogens are biologically inactive, more polar than the parent
molecules, and readily excreted in urine and bile [220].
Sulfonation: Sulfate conjugation (sulfonation) is an important pathway in the
biotransformation of many hormones, neurotransmitters, and xenobiotic compounds
[222]. Sulfonation reactions are catalyzed by members of two distinct enzyme
superfamilies: ⑴

the membrane-bound sulfotransferases, located in the Golgi

apparatus, that catalyze the sulfonation of proteins, peptides and glycosaminoglycans
and ⑵ the cytosolic sulfotransferases (SULTs) that metabolize xenobiotics and
endogenous compounds such as estrogens [223-225]. The SULT superfamily is divided
into families that are designated by Arabic numerals; SULT family members share at
least 45% amino acid sequence identity [226]. Each family can then be further
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subdivided into subfamilies that are designated by capital letters; SULTs in the same
subfamily share at least 60% amino acid identity. Individual SULT enzymes within
subfamilies are then identified using Arabic numerals [226-230]. SULTs catalyze the
transfer of a –SO3 group from the cosubstrate 3'-phosphoadenosine-5'-phosphosulfate
(PAPS) to the hydroxyl group of sulfonation targets [231].
Extensive biotransformation of endogenous and exogenous estrogens to
sulfonated conjugates, especially the most abundant circulating estrogen sulfates, has
long been recognized as a major route of estrogen metabolism in humans [232].
Estrogen sulfonation decreases estrogenic activity by facilitating estrogen excretion and
blocking ER-mediated activity [233-235]. Estrogen sulfotransferase activity has been
detected in various human tissues, including liver, small intestine, kidney, uterus,
adrenal gland, and breast [236-238]. The in situ sulfonation of estrogen in estrogen
target tissues contributes significantly to estrogen bioavailability in those tissues [239].
Several studies have associated SULT activities with breast cancer, although there are
some contradictory findings [240-244].
There

are

mainly three

SULTs,

SULT1E1

(also

known

as estrogen

sulfotransferase), SULT1A1 (as known as phenol-sulfotransferase) and SULT2A1 (also
known as DHEA sulfotransferase), which can catalyze the sulfonation of E1 and E2 with
different affinities [224;228;245]. Among the SULTs, SULT1E1 exhibits the highest
affinity for estrogen, especially the potent E2, and is the only SULT that sulfonates
estrogen at physiological nanomolar concentrations of the hormone [246-248].
SULT1E1 is highly expressed in normal human breast epithelial cells, but its expression
is often attenuated in breast cancer and malignant breast cancer cell lines [249-251].
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SULT1E1 immunoreactivity has been shown to correlate negatively with tumor size and
to associate significantly with a reduced risk of recurrence or improved prognosis [97].
SULT1A1 and, to a lesser extent, SULT2A1 are the main forms of SULT expressed in
breast tumors [249;252;253]. However, SULT1A1 sulfonates E2 at micromolar
concentrations; the affinity of SULT1A1 for E2 is about 300-fold lower as compared to
SULT1E1 [254]. Therefore, SULT1E1 is the primary SULT that regulates the availability
of estrogens in the breast and consequently affects cell growth, and abnormal
expression of SULT1E1 may contribute to the development and growth of breast
carcinomas. This hypothesis has been supported by the finding that forced SULT1E1
expression in the human breast cancer cell line MCF7 significantly suppressed E2stimulated cell proliferation and DNA synthesis, suggesting that breast tumors may
maximize E2 levels in situ to promote tumor growth by suppressing the expression of
SULT1E1 [255]. To date, little is known about the regulation of SULT1E1 expression.
3

MCF10A model
The MCF10A-derived lineage of human breast epithelial cell lines is a good

model to study the molecular events that occur during breast cancer progression
because these cell lines were all derived from a common genetic background and the
model includes the full spectrum of neoplastic progression and incorporates aspects of
both indolent preneoplastic diseases to aggressively neoplastic breast epithelial cell
growth.
The pathology of breast cancer tumorigenesis is a multistep sequential process
that begins with the development of hyperplasia, subsequent progression through
ductal carcinoma in situ (DCIS), and finally malignant invasive carcinoma (Fig. 1.2). In
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support of this progression model, several studies have demonstrated that the risk for
later breast carcinoma and the frequency of molecular changes involving cell-cycle
regulation and apoptosis that are found in malignant invasive cancer are both increased
during progression in this continuum [256-262].

Fig. 1.2 The progression processes of human breast cancer. (Figure adapted from
Burstein,H.J., et al, N.Engl.J.Med, 350, 1430-1441)
1)

Hyperplasia: Within the mammary gland there is a vascularized fibro-fatty stroma

supporting a complex network of branching ducts at the end of which is the functional
unit of the breast, the terminal duct lobular unit (TDLU). It has been shown
morphologically that most of the benign and malignant epithelial proliferations in the
breast are derived from the TDLU [263]. The normal TDLU is lined by two cell layers
consisting of an inner cuboidal epithelium, and an outer myoepithelial cell layer (also
named the basal layer). These cells form a distinct luminal border around the empty
space of the breast duct. Any proliferation that results in an increase of more than the
normal 2 layer system is called hyperplasia [264].
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Hyperplasia is usually the first step in the progression toward breast cancer and
it can be further classified as 'typical' (also called usual ductal hyperplasia), including
mild hyperplasia (2-4 layers of epithelial cells), moderate hyperplasia (4 or more layers
of epithelial cells) and florid hyperplasia (Fig. 1.3) or 'atypical' [265]. About 60% of
„typical‟ hyperplasia has ER over-expression in most of the cells compared with normal
epithelium [266-268]. However, only the atypical hyperplasia (AH) variety is of concern
for possible breast cancer [269;270].

Fig. 1.3 Histological features of hyperplasia. Picture adapted from Dawson et
al [319].
With florid hyperplasia, the lumen is distended and irregular, and the luminal
spaces are filled or partially filled with proliferating epithelial cells [271;272]. The
individual cells vary in size and shape from ovoid to spindle, elongated reniform, but
with normal chromatin pattern and indistinct nucleoli [271;272]. Florid hyperplasia is
associated with a 2-fold increased risk of breast cancer compared with the general
population in the same age pool [256;271].
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AH (Fig. 1.4) is an intermediate stage between hyperplasia of the usual type and
DCIS. Therefore, AH contains cytological and architectural features of both of these
other stages [273]. For example, AH has distended ducts, a population of relatively
uniform small- or medium-sized round, cuboidal or polygonal cells, enlarged but evenly
distributed hyper-chromatic nuclei, marked cellular proliferation and a regular micropapillary configuration [273]. Mitoses, particularly abnormal forms, are infrequently seen
[273].
AH is considered to be precancerous and can be detected more frequently in
malignant breasts than in benign breast disease
[274]. AH lesions have been reported to have an
increased proliferation and growth advantage
over

normal

epithelium,

which

has

been

attributed to the expression of a mutated,
estrogen hypersensitive ER [275]. It is clear that
AH is a rare condition only being seen in 4-5%
of benign biopsies but it confers a 4-5 time

Atypical Hyperplasia
Fig. 1.4 Atypical Hyperplasia.
Figure adapted from Dawson et
al [319].

increased chance of developing breast cancer when compared with an age-matched
general population [276;277].
The specific criteria for distinguishing „typical‟ hyperplasia from AH have been
well established [256]. „Typical‟ hyperplasia is characterized by cellular variability,
nuclear overlap, and indistinct cell borders [256].
2)

DCIS: „Typical‟ and „atypical‟ hyperplasia and DCIS have traditionally been

categorized as intraductal proliferative lesions [276]. After the onset of mammography
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screening, DCIS accounted for about 20% of all breast cancers detected in North
America [278;279]. DCIS is a pre-invasive malignant proliferation of breast epithelial
cells and has been demonstrated to be the
evolutionary origin of invasive cancers because
both of them present the same chromosomal
alterations [280;281].
In this stage (Fig.1.5), ducts are grossly
distended by tumor cells and the central area
occasionally shows extensive comedo necrosis.
DCIS shows a micro-papillary growth pattern and

Ductal Carcinoma in situ
Fig. 1.5 Figure adapted from
Dawson et al [319].

forms rigid intraluminal bridges with well-defined round spaces. The epithelial cells of
DCIS tend to have distinct cell boundaries and become monomorphic. Chromosomal
imbalance, prominent and multiple nucleoli, and enlarged nuclei are also seen in this
stage. DCIS lacks evidence for invasion across the basement membrane, which can be
confirmed by immunohistochemical (IHC) assessment of markers of the myoepithelial
cell layer and the basement membrane surrounding the ductal lumen [282;282].
However, it has been reported that high-grade DCIS is remarkable for the break down

Comedo DCIS

Solid with necrosis
DCIS

Cribriform DCIS

Cribriform DCIS
with necrosis

Micropapillary DCIS

Fig.1.6 Comedo, solid, cribriform, and micropapillary ductal carcinoma in situ.
Picture adapted from Bellamy et al [287].

25
of the myoepithelial cell layer and basement membrane surrounding the ductal lumen
[283].
The expression profile of genes and proteins that are involved in cell
proliferation, differentiation, signal transduction, interaction between cells and the
surrounding extracellular matrix, and intracellular transport has been characterized and
compared among different stages of breast cancer progression [284;285]. The data
indicate that most of the critical changes during breast tumorigenesis happen in DCIS
and prior stages [285]. A recent study showed that high grade DCIS had a greater
tendency to be HER2 positive and basal-like than lower grade DCIS, which indicates
that DCIS may be the precursor of basallike invasive breast cancer [286].
It is well accepted that DCIS
consists of a heterogeneous range of
lesions

with

diverse

histopathological

features, genetic alterations, molecular
biomarkers,

and

the

chance

of

progression to invasive cancer. Various
systems have been used to classify

Low grade

Intermediate
grade

High grade

Fig. 1.7 Nuclear grading. Picture
adapted from „Breast Pathology on the
Web‟

DCIS. The traditional classification is mainly based on architectural growth pattern and
nuclear grading [287]. According to this system, DCIS can be further classified as
comedo, solid, cribriform, micropapillary and papillary DCIS [287;288] (Fig. 1.6).
However, this system provided poor reproducibility and inadequate ability to predict the
potential for progression to invasive disease. Therefore, numerous updated
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classification criteria have been proposed mainly based on lesion size, nuclear grading,
necrosis, calcification, cytonuclear features and molecular bio-markers [289-293]. It is
important to note that nuclear grading is the single criterion that has been shown to
associate closely with recurrence after surgical excision of DCIS. As shown in Fig. 1.7,
nuclei were graded into three levels:
Low grade: Nuclei are spherical, monotonous in appearance, small and
centrally placed. Chromatin is finely distributed and mitoses are rare [294].
High grade: Nuclei are irregular in shape, pleomorphic, large and varied
in size. Coarse chromatin, prominent multiple nucleoli and frequent
mitoses are also commonly found in this level [294].
Intermediate grade: Nuclei show features in between those described for
low and high grade [294].
In summary, based on the criteria described above, DCIS can be further
classified into two grades. High grade DCIS is comprised of a group of atypical cells
with high or intermediate grade nuclei and exhibits several growth and architectural
patterns, including solid, micropapillary and cribriform. Comedo-type central necrosis
with calcification is common in this grade. High grade DCIS tends to be ER-negative
and HER2-positive and contains a series of other genetic changes [295-297]. Low
grade DCIS contains a population of proliferative monomorphic cells with low grade
nuclei, and the cells are generally arranged in micropapillary and cribriform patterns.
This grade of DCIS is frequently ER-positive [298;299].
Low grade DCIS and AH are morphologically and histologically similar and hard
to distinguish. However, low grade DCIS is associated with a significantly higher risk of
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invasive breast cancer development compared to AH [270;271]. Therefore, it is clinically
important to separate low grade DCIS from AH. The diagnostic distinction between AH
and DCIS is fundamentally based on the extent of involvement (Fig. 1.8). If the
proliferative cell amount is limited and does not congest the entire duct space, AH is
identified [270;276]. DCIS is diagnosed if the cellular proliferation involves two or more
adjacent duct spaces and is at least 2 mm in aggregate length [300].

Atypical ductal hyperplasia

Ductal carcinoma in situ

Fig. 1.8 The diagnostic distinction between atypical ductal hyperplasia
and ductal carcinoma in situ. Picture adapted from Wiechmann,L. and
Kuerer, H.M., 2008, Cancer, 112, 2130-2142.
3)

Invasive breast cancer: Invasive breast cancer is an extremely heterogeneous

disease in its rate of proliferation, nuclear morphology, stromal response, pattern of
infiltration, degree of differentiation and clinical course. Different types of carcinoma
have distinct prognostic outcomes and treatment options [301]. For example, tubular
carcinoma and papillary carcinoma have a better prognosis compared with invasive
ductal carcinoma, not otherwise specified [302].
Thanks to microarray technology, the molecular changes that enable normal
epithelial cells to progress to invasive, metastatic disease are increasingly well
understood [303;304] and the gene expression profiles are used to discriminate
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different subtypes of breast cancer. According to ER-expression (normally expressed
by luminal breast epithelial cells), breast cancer can be divided into two groups: ERpositive and ER-negative [284;303;305]. The risk factors, precursors, clinical behaviors
and outcomes differ between ER-positive and ER-negative breast cancers [306-311].
The ER-negative group can be further subdivided into: basal-like, HER2-positive and
normal-like tumors [284;303;305]. Basal-like breast cancers, a subtype originating from
the basal epithelial layer, overlap with the so called triple-negative breast cancer
(TNBC) (ER-, PR-, and HER2-negative). TNBC has become a focus of intense
research since TNBC patients have a younger age at onset, higher tumor grade, larger
tumor size, and increased propensity to develop metastases. Most importantly, they
lack the three most significant therapeutic markers for clinical management resulting in
the worst outcome when compared with other cancer subtypes [168;216;306;312;313].
The MCF10A-derived lineage of human breast epithelial cell lines is a good
model to study TNBC because the resulting cancer cell lines of this lineage (MCF10CA)
are triple negative [314;315]. This model mimics the development of human breast
carcinoma from benign hyperplasia through AH to DCIS and eventually to malignant
invasive tumors with the potential to metastasize. The parental MCF10A cell line was
derived from spontaneously immortalized breast epithelial cells that were obtained from
a donor with benign proliferative breast disease [315]. MCF10A cells are ER negative,
near diploid and non-tumorigenic because MCF10A cells do not give rise to persistent
lesions when xenografted into immunodeficient mice [315-317]. The MCF10A cell line
has been used extensively as a model of normal breast epithelial cells because they
maintain typical breast epithelial characteristics such as formation of acini in collagen,
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lack of anchorage-independent growth, and requirement for hormones and growth
factors to grow in culture [316].

MCF10AT1
MCF10CA1a

Trocar
Fibrocystic
Breast

MCF10A

T24 Ras
Transfection

MCF10
AneoT

MCF10CA1b

MCF10A
T1k.cl2

MCF10CA1d
MCF10CA1h

MCF10
DCIS.com

MCF10CA2

Normal

Premalignant

Malignant

Fig. 1.9 The production of MCF10A lineage Human Breast Cancer Cell Lines.
Figures adapted from [318,319]. The parental MCF10A cell line was derived from
spontaneously immortalized breast epithelial cells that were obtained from a
donor with benign proliferative breast disease. In vitro stable transformation of
MCF10A cells with the mutated c-Ha-ras oncogene resulted in development of
the premalignant MCF10AneoT cell line. Serial passage of xenograft lesions
formed by MCF10AneoT cells led to the establishment of preneoplastic
MCF10AT1 and MCF10AT1Kcl2 cell lines. A 292-day old MCF10AT1Kcl2
xenograft that progressed to adenocarcinoma was the source of the malignant
MCF10CA variant series after serial passage of humor pieces. The
MCF10DCIS.com cell line was developed by cloning of one of the malignant
variants, MCF10CA1h
In vitro stable transformation of MCF10A cells with the mutated c-Ha-ras
oncogene resulted in development of the premalignant MCF10AneoT variant cell line
that slowly generates simple ductal lesions within 7-8 weeks when xenografted into
nude mice (Fig. 1.9) [56]. Serial passage of xenograft lesions formed by MCF10AneoT
cells led to the establishment of preneoplastic MCF10AT1 and MCF10AT1Kcl2 cell
lines [318]. The MCF10AT1 cell line was established from a 100-day old MCF10AneoT
squamous carcinoma explant lesion. When xenografted into nude mice, MCF10AT1
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cells produced a spectrum of preneoplastic lesions, including AH and DCIS [317].
MCF10AT1 cells demonstrate a ~25% incidence of invasive cancers in xenograft
lesions that develop over an extended period of time [319]. The MCF10AT1Kcl2 cell
line was established from a 367-day old MCF10AneoT adenocarcinoma xenograft
lesion. The MCF10AT1K.cl2 variant retained an MCF10AT1-type pattern of xenograft
growth but also displayed chromosomal aberrations more characteristic of genetic
instability and could form hyperplastic lesions more rapidly [318].
A 292-day old MCF10AT1Kcl2 xenograft that progressed to adenocarcinoma
was the source of the malignant MCF10CA variant series after serial passage of tumor
pieces. Rather than forming simple ducts, MCF10CA variants rapidly form highly
proliferative invasive carcinomas at an incidence of 100% [318]. The MCF10DCIS.com
cell line was developed by cloning of one of the malignant variants, MCF10CA1h [320].
MCF10CA1h was derived from a lesion formed by two successive trocar passages of a
lesion formed by premalignant MCF10AT cells. Injection of MCF10DCIS.com cells into
immunodeficient mice produces rapidly growing lesions that are consistent with the
poor prognosis comedo-type DCIS and invariably progress to invasive cancer [320].
4.

Statement of problem
Despite a growing understanding of SULT1E1‟s function in steroid hormone and

drug metabolism, the role of SULT1E1 in the malignant progression of breast epithelial
cells is still unknown. We previously reported that SULT1E1 mRNA was expressed in
the “normal” breast epithelial MCF10A cells and in the preneoplastic MCF10AT1 and
MCF10AT1Kcl2 cell lines [250]. However, the expression was “switched off” in the more
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neoplastically progressed variant cell lines, beginning with the MCF10CA1a cell line
[250]. Thus, MCF10AT1 cells that have preserved SULT1E1 expression and E2-ER
regulated growth can be used to determine the impact of SULT1E1 expression on
tumorigenicity. In the same study, we observed a proliferation state-dependent
expression of SULT1E1 in MCF10A cells [250]. Therefore, the regulatory mechanism
for this phenomenon was also investigated.
The results of this research will provide new information on the role of SULT1E1
in breast cancer progression. Since SULT1E1 has high affinity for physiological
concentrations of estrogen, SULT1E1 may represent a good target for the prevention
and treatment of breast cancer in humans.
Chapter 2 of the dissertation discusses the expression of estrogen-metabolizing
genes including cytosolic sulfotransferases (SULT1E1, SULT1A1, SULT2A1, and
SULT2B1), STS, CYP19, 17β-hydroxysteroid dehydrogenases (17βHSD1 and 2),
CYP1B1, and catechol-O-methyltransferase (COMT) in the MCF10A-derived lineage
cell culture model for basal-like human breast cancer progression and in ERα-positive
luminal MCF7 breast cancer cells. Chapter 3 delineates the role of the aryl hydrocarbon
receptor (AhR) in the transcriptional regulation of SULT1E1 in the non-tumorigenic
MCF10A cell line. In chapter 4, the mechanism underlying tobacco smoke condensate
(TSC)-mediated down-regulation of SULT1E1 expression in MCF10A cells is
discussed. In chapter 5, the impact on tumorigenesis of SULT1E1 knock-down in the
MCF10AT1 xenograft model is presented.
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CHAPTER 2

Expression of estrogenicity genes in a lineage cell culture model
of human breast cancer progression

INTRODUCTION
The estrogen sensitive nature of breast cancer was observed by Beatson over
100 years ago [321]. Prolonged cumulative exposure to estrogen during a woman‟s
lifetime is a significant risk factor for the development of breast cancer [322]. Estrogen
stimulates cell growth through ER-mediated events, which can enhance opportunities
for DNA mutation. In addition, reactive estrogen metabolites generated by cytochrome
P450-mediated catalysis, such as estrogen catechols and quinones, can directly induce
mutations [167]. Particularly in post-menopausal women who lack ovarian sources of
estrogen, the factors that govern intra-tissue metabolism of biologically active estrogen
(i.e., estrogen “intracrinology”) are important therapeutic targets and biomarkers for
breast cancer progression [323]. Determinants affecting the amount and activity of
estrogen in breast tissue include expression of the major forms of estrogen receptor
(ERα and ERβ), cytosolic sulfotransferases (SULTs), STS, CYP19, 17β-hydroxysteroid
dehydrogenase types 1 and 2 (17βHSD1 and 17βHSD2), CYP1B1, and COMT (Fig. 2.1
adapted from [246;324;325]).
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Fig. 2.1 Pathways of estrogen metabolism, bioactivation, and action.
CYP19 (aromatase) catalyzes the aromatization of androstenedione and
testosterone to form estrone (E1) and 17β-estradiol (E2), which can bind to and
activate ER. Of the cytosolic SULTs, SULT1E1 preferentially catalyzes the
sulfonation of E1 and E2 with high efficiency. Sulfonated estrogens are ERinactive. Steroid sulfatase (STS) catalyzes the deconjugation of sulfonated
steroids and favors the formation of biologically active estrogen. STS and 3-βhydroxysteroid dehydrogenase (3βHSD isomerase) function in the formation of
sex steroids from precursor hormones, such as dehydroepiandrosterone sulfate
(DHEA sulfate) and dehydroepiandrosterone (DHEA). 17βHSD1 reduces E1 to
the more potent E2, while 17βHSD2 oxidizes E2 to E1. The 4-hydroxylation of
E2 is catalyzed by CYP1B1; E2 2-hydroxylation is catalyzed by CYP1A1.
Catecholestrogens auto-oxidize to form mutagenic orthoquinone electrophiles
that can be detoxified via COMT-mediated conjugation.
This study, published in Breast Cancer Research and Treatment [250], was
designed to elucidate the expression of determinants of estrogen activity in MCF10A
derived lineage cell culture model that captures the heterogeneity of breast cancer
progression in humans.
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The molecular phenotypic characteristics of the MCF10A lineage indicate that
this is a model of basal breast cancer, in that the resulting MCF10CA1 cancer cell lines
are triple negative (i.e., do not express ER, PR or HER2/neu) [314;315]. Nevertheless,
xenograft studies have demonstrated that progression of preneoplastic MCF10AT1
cells is sensitive to estrogen manipulation [319;326-328]. Estrogen has been shown to
alter signal transduction in triple negative MDA-MB-231 (do not express ERα; do
express ERβ) and SKBR3 cells (express neither ERα nor ERβ), causing activation of
the extracellular signal regulated kinases, ERK1 and ERK2 [147]. Both estrogen and
EGF induced phosphorylation of c-raf and ERK1/2 while stimulating the proliferation of
SKBR3 cells [329], and the two agents were more effective in combination. Importantly,
growth of ERα-negative breast cells was induced by the same 17β-estradiol (E2)
concentration (10−9 M) that stimulates ERα-positive MCF7 cells, whereas a higher
concentration (10−6 M) inhibited the growth of MDA-MB-231, and SKBR3 cells, and this
inhibition was additive with heregulin [330].
Although MCF7 requires supplementation with E2 to mimic pre-menopausal
human serum levels (typically 400–1,500 pg/ml) to achieve xenograft growth in nude
mice, MCF10AT1 forms lesions that progress to atypical hyperplasia, DCIS and
invasive ductal carcinoma without E2 supplementation. Serum E2 levels in nude mice
are typically less than 50 pg/ml [331], which mimics post-menopausal human serum
levels [332]. However, MCF10AT1 cells form lesions consisting only of simple ducts in
ovariectomized (OVX) nude mice [333], which have serum E2 levels of ~5 pg/ml [334].
Therefore, MCF10AT1 xenografts respond to very low doses of E2 in vivo, suggesting
that the levels of estrogen-processing enzymes in breast cells may play a critical role in
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determining growth response. Therefore, an analysis of the determinants of
estrogenicity in MCF10A lineage cell lines was undertaken to provide insight into the
dynamic changes in estrogen responsiveness that occur during basal breast cancer
development.
Histone deacetylases (HDACs) are being increasingly recognized for their
important roles as transcriptional modulators of pro-survival pathways during breast
cancer progression [335]. HDAC inhibitors, such as Vorinostat, Valproic acid, and
Panobinostat, are currently tested in many phase I and II clinical trials as single agents
as wells as in combination schemes in the treatment for breast cancer. They have
demonstrated to have promising antitumor activity, favorable clinical effects and, most
importantly, encouraging activity in reversing hormone resistance [336-339]. However,
their effects on the expression of estrogen metabolism machinery during breast cancer
progression are unknown. Therefore, the effects of treatment with trichostatin A (TSA),
a potent HDAC inhibitor, on ER and estrogen metabolism gene expression in the
MCF10A lineage cell lines were also investigated.

Materials and methods

Materials. TaqMan Gene Expression reagents were purchased from Applied
Biosystems (Foster City, CA). qPCR Human Reference Total RNA was purchased from
Clontech Laboratories (Mountain View, CA). Culture media, sera, L-glutamine, sodium
pyruvate,

penicillin-streptomycin,

anti-SULT1E1

antibody,

recombinant

human

SULT1E1, Superscript II, and Lipofectamine 2000 were purchased from Invitrogen
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Corporation (Carlsbad, CA). EGF was purchased from BD Biosciences (San Jose, CA).
Recombinant human insulin (Novolin R) was purchased from Novo Nordisk
Pharmaceuticals, Inc. (Princeton, NJ). Cholera toxin, hydrocortisone and TSA were
purchased from Sigma–Aldrich (St. Louis, MO). Horseradish peroxidase-conjugated
goat anti-rabbit IgG was purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
ECL Plus Western Blotting Detection Reagents and Hybond-P membranes were
purchased from GE Healthcare (Piscataway, NJ). Other materials were obtained from
the sources indicated below.
Cell culture. MCF7 and MCF10A lineage (MCF10A, MCF10AT1, MCF10AT1K.cl2,
MCF10CA1a, MCF10CA1d and MCF10DCIS.com) cell lines were obtained from the
Cell Resources Facility of the Barbara Ann Karmanos Cancer Institute, Wayne State
University. MCF10A lineage cell lines were cultured in phenol red-free Dulbecco‟s
Modified Eagle Medium/Ham‟s F12 (DMEM/F12) nutrient mixture (1:1) supplemented
with 10 μg/ml insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone,
5% horse serum, 100 U/ml penicillin, and 100 μg/ml streptomycin. MCF7 cells were
cultured in phenol red-free Minimum Essential Medium supplemented with 10 μg/ml
insulin, 1 mM sodium pyruvate, 10% calf serum, 100 U/ml penicillin, and 100 μg/ml
streptomycin. Cell lines were routinely maintained in T75 flasks in a 37°C humidified
environment of 5% CO2/95% air. For experiments, 250,000 cells were plated into
60 mm dishes. For pre-confluent cultures (~70% confluency), cells were harvested
2 days after plating. Confluency was reached approximately 5 days after plating. On
day 7, confluent cultures were harvested for preparation of total RNA. Experiments
were conducted at a cell density of 70% confluency unless otherwise indicated. For

37
TSA studies, 24 hr after plating, cells were treated with 0.1% dimethyl sulfoxide (DMSO
control) or TSA.
TaqMan Gene Expression assays. Total RNA was prepared from individual dishes of
cells using the RNeasy Mini Kit (Qiagen, Valencia, CA). RNA samples were reverse
transcribed using Superscript II. Transcript levels were measured using the following
TaqMan Gene Expression Assays: Hs01046818_m1 (ERα), Hs00230957_m1 (ERβ),
Hs00193690_m1

(SULT1E1),

Hs00419411_m1

(SULT1A1),

Hs01105284_m1

(SULT2B1), Hs00234219_m1 (SULT2A1), Hs00165853_m1 (STS), Hs00240671_m1
(CYP19), Hs00166219_g1 (17βHSD1), Hs00157993_m1 (17βHSD2), Hs00164383_m1
(CYP1B1), and Hs00241349_m1 (COMT). Each PCR reaction included 2 μl of cDNA
template, a primer/probe (5-carboxyfluorescein fluor, minor groove binder quencher) set,
a primer-limited primer/probe (VIC-minor groove binder) set for 18S rRNA and Universal
PCR master mix, and amplifications were performed using an ABI Prism 7500
Sequence Detection System. Thermocycling parameters were 94°C for 10 min, and
40 cycles of 95°C for 15 s and 60°C for 1 min. Cycle threshold (Ct) values were
obtained using the SDS software package. For each sample, ΔCt was obtained by
subtracting the Ct of 18S rRNA from the Ct of target mRNA. Then, ΔΔCt values were
calculated by subtracting the ΔCt of the calibrator to which the other samples were
compared from the ΔCt of each sample. Mean relative quantitative expression values
were then calculated as 2

−ΔΔCt

.

Western blot and enzyme activity analyses. Cells in T75 flasks were washed with
and scraped into ice-cold phosphate-buffered saline (PBS). Cells were pelleted and
homogenized by sonication in buffer (200 μl per flask) consisting of 50 mM Tris–HCl,
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25 mM sucrose, 1 mM EDTA and 1× Halt protease inhibitor (Thermo Fisher Scientific,
Rockford, IL), pH 7.4. Homogenates were centrifuged at 20,000×g at 4°C for 20 min,
and supernatants were used for western blot analysis. Protein concentrations were
measured using the BCA Protein Assay (Thermo Fisher). Western blot analysis of
SULT1E1 content was accomplished as described previously [340], using 30 μg of
sample protein and polyclonal anti-SULT1E1 antibody. Uniform protein loading and
transfer were verified using Ponceau S staining. SULT1E1 catalytic activity was
measured in whole cell lysates prepared from MCF10CA1a cells as described [341].
Transient transfection analysis. The p2ERE-luc reporter was constructed by ligating
a double-stranded oligonucleotide containing two vitellogenin ERE upstream of a
minimal herpes simplex virus thymidine kinase promoter, which had been preligated
into pGL3-Basic (Promega Corporation, Madison, WI). The sequences of the
oligonucleotides are: 5′-CGCGTGTCCAAAGTCAGGTCACAGTGACCTGATTCAGGTC
ACAGTGACCTGATCAAAGTTA-3′ and 5′-GATCTAACTTTGATCAGGTCACTGTGACC
TGAATCAGGTCACTGTGACCTGACTTTGGACA-3′.
MCF7 cells (400,000) were seeded into 12-well plates and cultured in 2 ml
phenol red-free Minimum Essential Medium supplemented with 10 μg/ml insulin, 1 mM
sodium pyruvate and 10% charcoal-stripped fetal bovine serum. The following day,
Opti-MEM containing a premixed complex of 4 μl of Lipofectamine 2000, 1.6 μg
p2ERE-Luc and 1.25 ng pRL-SV40 (Promega) was added to each well. The following
day, cultures (5 wells per group) were incubated with phenol red-free Minimum
Essential Medium, supplemented as described above, containing 0.1% DMSO, 10 nM
E2, 300 ng/ml TSA, or E2 and TSA in combination. After 48 hr, the cells were harvested
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for measurement of firefly and Renilla luciferase activities using the Dual Luciferase
Reporter Assay System (Promega) and a Dynex model MLX Luminometer.
Statistical analysis. Data were analyzed using the paired t-test or one-way analysis of
variance followed by the Newman–Keuls test using Prism (GraphPad Software, San
Diego, CA).
Results

The high catalytic efficiency of SULT1E1 toward E2 sulfonation supports a major

Fig. 2.2 Expression of SULT1E1 mRNA and protein in the MCF10A-derived
lineage cell culture model for breast cancer progression and in MCF7 cells.
A: A TaqMan Gene Expression assay was used to determine the relative levels of
SULT1E1 mRNA in subconfluent (70%, white bars) and confluent (100%, black
bars) MCF10A series cells (from left to right, MCF10A, MCF10AT1,
MCF10AT1K.cl2, MCF10CA1a, MCF10CA1d and MCF10DCIS.com) and in
MCF7 cells. SULT1E1 mRNA content is expressed relative to the level measured
in subconfluent MCF10A cells, and all values represent the mean ± SEM of three
independent cell culture experiments. Groups labeled with different letters are
significantly different from each other (P < 0.05). B: Representative Western
blots showing the relative amounts of SULT1E1 immunoreactive protein in
subconfluent MCF10A-derived cell lines.
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role for SULT1E1 in the in situ inactivation of E2 within the breast. SULT1E1 mRNA
was detected in parental MCF10A cells, although the level of expression was highly
dependent upon the confluency of the cultures. Relative to pre-confluent MCF10A cells,
the amount of SULT1E1 mRNA in confluent cells was significantly increased by ~16fold (Fig. 2.2A). SULT1E1 mRNA expression was robust in MCF10AT1 cells, and unlike
MCF10A cells, was not significantly affected by confluency (Fig. 2.2A). SULT1E1
mRNA expression was also substantial in MCF10AT1K.cl2 cells, but was markedly
diminished in MCF10CA1a, MCF10CA1d, MCF10DCIS.com, and MCF7 cells
(Fig. 2.2A). SULT1E1 immunoreactive protein levels in the MCF10A lineage cell lines
were in accord with the corresponding mRNA levels (Fig. 2.2B). Since STS and other
cytosolic SULTs have been implicated in the modulation of breast intracrinology
[79;97;254;341-343], the expression patterns of STS and SULTs 1A1, 2A1, and 2B1
were characterized. STS mRNA was detected across the MCF10A series cell lines, as
well as in MCF7 cells (Fig. 2.3A). SULT1A1 and SULT2B1 transcripts were detected
only in MCF7 cells, while the mRNA for SULT2A1, an enzyme that is highly expressed
in human liver and adrenal gland [342], was not detected in any of the breast cell lines
(Fig. 2.3B). 17βHSD1 catalyzes the reduction of estrone (E1) to the more potent E2,
while 17βHSD2 catalyzes the oxidation of E2 to E1 [344]. 17βHSD1 mRNA was
detected in all cell lines but was highest in the MCF10CA1a and MCF10DCIS.com cells
(Fig. 2.3B). By contrast, 17βHSD2 mRNA was expressed most abundantly in the
parental MCF10A cell line (Fig. 2.3B).
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Fig. 2.3 Expression of estrogen metabolism enzymes in MCF10A series and
MCF7 cell lines. TaqMan Gene Expression assays were used to determine the
relative levels of STS, SULT1A1, SULT2B1, SULT2A1 (A), 17βHSD1, 17βHSD2 (B),
CYP19, CYP1B1, and COMT (C) mRNA in pre-confluent MCF10A series cell lines
and in MCF7 cells. The mRNA levels are expressed relative to their respective levels
in MCF10A cells, MCF7 cells or a human RNA reference pool (HRP). All values
represent the mean ± SEM of three independent cell culture experiments. For all
transcripts except 17βHSD2 and CYP1B1: Groups labeled with different letters are
significantly different from each other (P < 0.05). For 17βHSD2 and CYP1B1:
*** Significantly different from all other groups, P < 0.001. When the group labeled
with *** was omitted from the analyses, groups labeled with different letters are
significantly different from each other (P < 0.05). For STS and COMT, no significant
differences among groups were detected. For SULT2A1 and CYP19, mRNA levels
were undetected in all cell lines.
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The transcript for CYP19, which catalyzes the aromatization of androstenedione
and testosterone to E1 and
E2, respectively [345], was
not detected in any cell line
(Fig. 2.3C). CYP1B1 is the
most active E2 hydroxylase
[346], and high levels of E2
hydroxylation in estrogenresponsive tissues may play
an

important

role

in

[177].

By

estrogen-related
tumorigenesis
contrast,

O-methylation

catalyzed by COMT is an
inactivation pathway for E2
catechols

and

quinones

[177]. CYP1B1 mRNA levels
were highest in MCF7 cells
(Fig. 2.3C).

Though

Fig. 2.4 ERα and ERβ mRNA expression in preconfluent MCF10A series and MCF7 cell lines.
TaqMan Gene Expression assays were used to
determine the relative levels of ERα (top) and ERβ
(bottom) mRNA. The mRNA contents of ERα and
ERβ are expressed relative to their respective levels
in MCF10A cells, and all values represent the
mean ± SEM of three independent cell culture
experiments. For ERα, groups labeled with different
letters are significantly different from each other
(P < 0.05). For ERβ, no significant differences among
groups were detected.

CYP1B1 mRNA also appeared to be higher in MCF10AT1 and MCF10AT1K.cl2 cells
than in the other MCF10A series cells (Fig. 2.3C), this difference was not maintained
when the cultures were treated with DMSO (experiment shown in Fig. 2.6). COMT
demonstrated relatively consistent mRNA expression across cell lines (Fig. 2.3C).
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Fig. 2.5 Effects of TSA treatment on ERα and ERβ mRNA expression in
MCF10A series and MCF7 cell lines and on E2-mediated activation of an
estrogen-responsive reporter gene. a Cell lines were treated for 24 h with 0.1%
DMSO (white bars) or 300 ng/ml TSA (black bars), and ERα and ERβ mRNA levels
were measured with TaqMan Gene Expression assays. ERα and ERβ mRNA levels
are expressed relative to the amounts measured in DMSO-treated MCF10A cells.
All values represent the mean ± SEM of three independent cell culture experiments.
*, ** Significantly different from the corresponding DMSO-treated group, P < 0.05
and P < 0.01, respectively. b MCF7 cells were transiently transfected with an
estrogen-responsive luciferase reporter plasmid. After transfection, cells were
treated with 0.1% DMSO, 10 nM E2, 300 ng/ml TSA, or E2 and TSA in combination
for 48 h. After treatment, cells were harvested for the measurement of luciferase
activities. Each bar represents the mean ± SEM of normalized (firefly/Renilla)
luciferase measurements (5 wells per treatment group) relative to the activity
measured in DMSO-treated cells. ** Significantly different from the E2-treated group
P < 0.01
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ER expression is a major determinant of estrogenic activity. As expected, the
ER-positive MCF7 cell line expressed ERα mRNA at a level that was >100-fold greater
than that detected in any of the MCF10A series cell lines (Fig. 2.4). ERα
immunoreactive protein is reportedly undetectable in MCF10A cells [314], and in the
present study ERα mRNA was detected at a low level in the MCF10A lineage cells
(Fig. 2.4). By comparison, ERβ mRNA levels were not abundant either in MCF7 cells or
in the MCF10A-derived series of cell lines (Fig. 2.4).
Since HDACs are important modulators of transcription and therapeutic targets
in breast cancer [335;339], the effects of TSA treatment were characterized on ER and
estrogen metabolism enzyme expression. As previously reported [347], TSA treatment
of MCF7 cells produced a dramatic decrease (>99%) in ERα mRNA expression
(Fig. 2.5A). The loss of E2 agonistic activity following TSA treatment was confirmed
using an ER-responsive reporter (Fig. 2.5B). By contrast, TSA treatment increased ERβ
mRNA levels in MCF7 cells by ~11-fold (Fig. 2.5A). TSA produced less pronounced
effects on ERα and ERβ mRNA expression in the MCF10A lineage cell lines
(Fig. 2.5A).
TSA also produced marked alterations in the mRNA expression of estrogen
metabolism enzymes in the cell lines. In the neoplastic MCF10CA1a cell line, where
SULT1E1 mRNA expression is substantially suppressed, TSA treatment produced a
concentration-dependent increase in SULT1E1 mRNA expression that correlated with
the induction of E2 sulfonation activity (Fig. 2.6A). TSA treatment increased SULT1E1
mRNA content by at least two-fold (2.3- to 26.1-fold) in all MCF10A series cell lines
except MCF10AT1, although the increase was statistically significant only for
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MCF10DCIS.com (Fig. 2.6B). TSA treatment also activated CYP19 expression in all of
the cell lines (Fig. 2.6C). By contrast, TSA treatment uniformly suppressed STS and
COMT expression (Fig. 2.6C). TSA treatment produced marked suppression of
SULT1A1, SULT2B1 and CYP1B1 mRNA levels in MCF7 cells, while SULT2A1
expression was induced in TSA-treated MCF7 cells (Fig. 2.6C). TSA treatment also
suppressed 17βHSD1 and 17βHSD2 expression in the MCF10A series cell lines that
demonstrated constitutive expression (Fig. 2.6C).
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Fig. 2.6 TSA treatment effects on estrogen metabolism enzyme expression in MCF10A
series and MCF7cell lines. A: Concentration-dependent effects of TSA treatment on
SULT1E1 mRNA expression in MCF10CA1a cells. MCF10CA1a cells were treated for 24 h
with 0.1% DMSO or with 75, 150 or 300 ng/ml TSA and harvested for measurement of
SULT1E1 mRNA levels with a TaqMan Gene Expression assay. All values represent the
mean ± SEM of three independent cell culture experiments relative to the amount measured
in the DMSO-treated cells. *** Significantly different from the DMSO-treated group,
P < 0.001. Inset Correlation of TSA-mediated changes in SULT1E1 enzymatic activity with
changes in SULT1E1 mRNA levels. B: MCF10A series and MCF7 cell lines were treated for
24 h with 0.1% DMSO or 300 ng/ml TSA and SULT1E1 mRNA levels were measured.
SULT1E1 mRNA contents are expressed relative to the level measured in DMSO-treated
MCF10A cells. All values represent the mean ± SEM of three independent experiments.
* Significantly different from the corresponding DMSO-treated group (P < 0.05). C: Cells
were treated as indicated in B and estrogen metabolism enzyme mRNA levels were
measured. STS, COMT, CYP1B1, 17βHSD1, and 17βHSD2 mRNA contents are expressed
relative to the respective levels measured in DMSO-treated MCF10A cells. SULT1A1 and
SULT2B1 mRNA levels are expressed relative to the levels measured in DMSO-treated
MCF7 cells. SULT2A1 mRNA levels are expressed relative to the level measured in TSAtreated MCF7 cells. CYP19 mRNA levels are expressed relative to the level measured in
TSA-treated MCF10A cells. All values represent the mean ± SEM of three independent
experiments. *, ** Significantly different from the corresponding DMSO-treated group,
P < 0.05 and P < 0.01, respectively
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Discussion

Selective ER modulators, selective ER down-regulators and inhibitors of
estrogen-producing enzymes, such as CYP19, STS, and 17βHSD1, represent
important classes of drugs for achieving estrogen blockade in the treatment of
hormone-responsive breast cancer [348-352]. In addition, HDAC inhibitors, which have
been shown to down-regulate ERα mRNA expression in MCF7 cells [347], are being
tested in phase II clinical trials that include patients with ER-positive metastatic breast
cancer progressing on endocrine therapy [336]. The combination of HDAC inhibitor and
tamoxifen were associated with low toxicity and reversed hormone resistance [336].
Despite an expanded range of targeted therapies, the critical alterations in breast
intracrinology that predispose patients to breast cancer development remain to be
elucidated.
In mammary tissue, stringent control of the powerful mitogen E2 is achieved
through the tight balance of ERα and ERβ expression coupled with titration of E2 levels.
Compared to ERβ, ERα is a high affinity receptor for estrogen [353]. Both ERα and ERβ
bind to the same response elements but produce differential effects on target gene
expression [354]. ERα is a recognized marker for E2-stimulated proliferation in breast
cancer [355]. Although further studies are needed to better assess the role of different
ERβ isoforms, emerging studies have associated ERβ with more aggressive breast
cancer types and poor clinical outcome [356-358]. In the present study, ERα expression
in the MCF10A lineage cell lines was low in comparison to its level in MCF7 cells, while
ERβ mRNA expression was comparably low among the cell lines. As previously
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reported [347], TSA suppressed ERα and induced ERβ expression in MCF7 cells.
However, TSA produced only modest effects on ERα and ERβ expression in the
MCF10A series of cell lines.
The pro-estrogenic machinery of the breast includes STS, CYP19, and
17βHSD1 [345;359]. Increased expression of STS occurs in 74% of breast cancer
biopsies and its presence correlates with an adverse prognosis [97]. In the present
analysis, STS mRNA levels were comparably detected across the MCF10A series of
cell lines and in MCF7 cells, and TSA treatment consistently tended to repress STS
expression.
CYP19 expression in breast tumor tissue facilitates a highly concentrated
estrogen micro-environment. Like STS, elevated CYP19 expression in breast tumor
tissue impairs prognosis [325]. Though CYP19 is more robustly expressed in breast
stroma, the application of fine resolution techniques has revealed the presence of
CYP19 in normal breast ductal epithelial cells and breast cancer cells, as well as in
intra-tumor stromal cells and peri-tumoral adipose tissue [360]. In the absence of TSA
treatment, CYP19 mRNA was not detected in MCF10A series cell lines or MCF7 cells.
In contrast to a previous report demonstrating a repressive role for TSA on CYP19
expression in MCF7 cells [361], this investigation revealed a TSA-inducible effect on
CYP19 expression in all of the cell lines examined.
There are at least fifteen 17βHSD enzymes that vary in catalytic range and
efficiency [362]. 17βHSD1 and 17βHSD2 are involved in the interconversion of E2 with
the less potent E1 [344]. Increased 17βHSD1 expression in breast cancer, either alone
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or in combination with CYP19, enhances estrogen concentrations and negatively
impacts prognosis [78;363], as does loss of 17βHSD2 expression [364]. In the present
study, the mRNA expression of pro-estrogenic 17βHSD1 was detected in MCF10A cells
but was more abundant in the neoplastic MCF10CA1a and MCF10DCIS.com variants.
By contrast, 17βHSD2 mRNA was most prominent in parental MCF10A cells. TSA
treatment produced only suppressive effects on 17βHSD1 and 17βHSD2 expression.
SULT1E1 is considered to be the predominant E2-inactivating enzyme in breast.
A previous survey of cytosolic SULT expression concluded that human mammary
epithelial cells expressed mainly SULT1E1, while breast cancer cell lines preferentially
expressed SULT1A1 and only trace amounts of SULT1E1 and SULT2A1 [249]. In an
independent study, SULT1E1 expression was reported in approximately 44% of human
breast cancer biopsy specimens [97]. The present investigation revealed SULT1E1
mRNA expression in confluent MCF10A cells and in the preneoplastic MCF10AT1 and
MCF10AT1K.cl2 cell lines. By contrast, SULT1E1 expression in the more neoplastically
transformed MCF10A-derived cell lines and in MCF7 cells was markedly repressed. As
previously described for CYP1A2 expression in MCF10A cells [365], SULT1E1 mRNA
levels were more abundant in confluent than in proliferating MCF10A cultures. The
constitutive expression of other steroid-metabolizing SULTs (i.e., SULT1A1, SULT2A1,
and SULT2B1) was not a prominent feature across the MCF10A-derived cell lines.
4-Hydroxylated estrogen metabolites produced by CYP1B1 metabolism are
particularly reactive and considered to be promutagenic [366]. CYP1B1 mRNA and
protein expression has been reported in up to 73% of human breast cancer biopsies
[367]. Increased CYP1B1 expression, coupled with the reduced expression of the
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detoxicating enzyme COMT, is associated with amplified breast cancer risk [366]. In the
current analysis, CYP1B1 mRNA was present at relatively low levels in the MCF10Aderived cell lines, but was more abundant in MCF7 cells, where its constitutive
expression has been previously described [368]. In contrast to a previous report
suggesting a stimulatory effect of TSA treatment on CYP1B1 expression in MCF7 cells
[369], the present study revealed TSA-mediated suppression for both CYP1B1 and
COMT in MCF7 cells. In contrast to the relatively restricted expression of CYP1B1,
COMT mRNA was widely detected across cell lines.
In aggregate, it appears that normal or early preneoplastic breast epithelial cells
act to minimize the mitogenic effects of E2 by retaining the expression of SULT1E1, a
major E2- inactivating enzyme, and by preserving the expression of the anti-estrogenic
dehydrogenase, 17βHSD2. Particularly in the MCF10A lineage model for breast cancer
progression where ERα levels are held to a minimum, the expression of key E2metabolizing enzymes is crucial for the establishment of the breast intracrine
environment. Within the progression model, the expression of pro-estrogenic STS and
17βHSD1 is maintained, while the capacity for in situ estrogen production through
aromatization is restrained. Based on the current study, several positive aspects of
HDAC inhibitor treatment in humans might be anticipated. These include the upregulation of SULT1E1 in neoplastic breast epithelial cells and also down-regulation of
pro-estrogenic metabolic enzymes such as STS and 17βHSD1. With HDAC inhibition,
the prominent expression of CYP1B1 that is observed in MCF7 cells becomes downregulated. However, as a counter-weight, the expression of the protective enzyme
COMT also becomes down-regulated.
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The results of this study demonstrate that established breast cancer cell lines,
such as MCF7, do not necessarily reflect the changes in estrogen metabolism that
occur in breast epithelial cells as they progress from benign proliferative breast disease
toward neoplasia. In order to harness the promise and potential power of combined or
sequential metabolically-targeted therapies in breast cancer intervention, it will be
become essential to understand and control the real-time dynamics that determine the
delicate balance of intracrine metabolism within the breast.
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CHAPTER 3

Regulation of SULT1E1 expression by confluency of MCF10A breast epithelial
cells: Role of the AhR

INTRODUCTION

The SULTs are a family of conjugating enzymes that catalyze the transfer of a
sulfuryl moiety from the activated physiological sulfate donor 3'-phosphoadenosine-5'phosphosulfate to the hydroxyl groups of endogenous and xenobiotic substrates,
including hormones, drugs, and procarcinogens [228;370]. One of the SULTs,
SULT1E1, catalyzes the sulfonation of estrogen at physiological concentrations.
SULT1E1 is an important determinant of a cell‟s response to estrogen because
sulfonated estrogen cannot bind to ERs [371]. In this manner, SULT1E1 expression in
breast epithelial cells likely limits the mitogenic effects of estrogen, thereby reducing the
risk for breast cancer development [341]. SULT1E1 is expressed in human breast
epithelial cells as well as in the MCF10A cell line, a model of normal human breast
epithelial cells, but is down-regulated in many breast cancer cell lines, suggesting that
this brake against estrogen mitogenicity is lost during neoplastic transformation
[250;341].
During the characterization of estrogenicity gene expression in MCF10A lineage
cell lines (Chapter 2), we observed that SULT1E1 mRNA content is markedly increased
when replicating MCF10A cells become confluent (Fig. 2.2) [250], indicating that
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SULT1E1 expression is regulated according to the confluency of these cells. By
comparison, in an earlier study in which the expression of cytochrome P450 transcripts
was profiled in MCF10A cells, two P450s, CYP1A1 and CYP1S1, were expressed in
pre-confluent MCF10A cells but not in confluent MCF10A cells [365]. Since both of
these P450s are transcriptional targets of the AhR [372], this finding suggests that AhR
is active in pre-confluent MCF10A cells but inactive in confluent MCF10A cells.
AhR agonist treatments cause suppression of SULTs in hepatic systems.
Treatment of female rats with 3-methylcholanthrene caused suppression of hepatic
hydroxysteroid sulfotransferase expression in parallel with CYP1A1 induction [373], and
treatment with β-naphthoflavone or 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) caused
suppression of hydroxysteroid sulfotransferase and aryl sulfotransferase expression in
primary cultured rat hepatocytes [374]. In a microarray analysis of TCDD treatment
effects on global gene expression in HepG2 human hepatoma cells, SULT1E1 mRNA
content was decreased by 60% following treatment with 10 nM TCDD for 8 hr [375].
Approximately the same magnitude of suppression occurred when the cells were pretreated with cycloheximide prior to TCDD treatment, suggesting that the reduction of
SULT1E1 mRNA content was a direct effect of TCDD treatment on gene transcription
and was not secondary to induction of a suppressive factor [375]. Most recently, TCDD
treatment was reported to cause suppression of SULT1E1 expression in the livers of
female C57BL/6 mice [376].
Taken together, these prior findings prompted us to hypothesize that AhR is the
molecular switch that confers confluency-dependent expression of SULT1E1 in
MCF10A cells. We propose that basally active AhR suppresses SULT1E1 transcription
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in pre-confluent MCF10A cells, while in confluent cells AhR becomes inactive, thereby
de-repressing SULT1E1 transcription.

Materials and Methods

Materials. TCDD was purchased from Midwest Research Institute (Kansas City, MO).
3‟-methoxy-4‟-nitroflavone (MNF) was purchased from ICC Chemical Corporation (New
York, NY). Cell culture medium, L-glutamine, horse serum, penicillin-streptomycin
solution, sodium pyruvate, Lipofectamine 2000, Superscript II, recombinant human
SULT1E1, and anti-SULT1E1 antibody were purchased from Invitrogen Corporation
(Carlsbad, CA). EGF was purchased from BD Biosciences (San Jose, CA).
Recombinant human insulin (Novolin R) was purchased from Novo Nordisk
Pharmaceuticals, Inc. (Princeton, NJ). Bromouridine (BrU), cholera toxin, doxycycline,
hydrocortisone, and puromycin were purchased from Sigma-Aldrich (St. Louis, MO).
Mouse monoclonal AhR antibody (B-11), goat polyclonal ARNT1 antibody (C-19), rabbit
polyclonal glyceraldehyde 3-phosphate dehydrogenase antibody (FL-335), and
horseradish peroxidase-conjugated goat anti-rabbit IgG, goat anti-mouse IgG, and
donkey anti-goat IgG were purchased from Santa Cruz Biotechnology (Santa Cruz, CA).
ECL Plus Western Blotting Detection Reagents and Hybond-P membranes were
purchased from GE Healthcare (Piscataway, NJ). The microRNA mimic (c-301032-010005 for hsa-miR-100* and c-300578-05-0005 for has-miR-221) was purchased from
Thermo Fisher Scientific. Other materials were obtained from the sources indicated
below.
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Cell culture. The MCF10A cell line was obtained from the Cell Resources Facility of
the Barbara Ann Karmanos Cancer Institute, Wayne State University and cultured in
phenol red-free DMEM/F12 Nutrient Mixture (1:1) supplemented with 10 μg/ml insulin,
20 ng/ml EGF, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone, 5% horse serum,
100 U/ml penicillin, and 100 μg/ml streptomycin. The cell line was routinely maintained
in T75 flasks in a 37°C humidified environment of 5% CO 2/95% air. For experiments,
125,000 cells or 1,000,000 cells were plated into 60 mm dishes. At these cell densities,
approximately 3 days after plating, pre-confluency (~70% confluency) or confluency
was reached, respectively, and the cells were harvested for preparation of total RNA.
For TCDD or MNF treatment, 48 hr after plating, cells were treated with 0.1% DMSO
(control), TCDD or MNF for 24h.
TaqMan Gene Expression assays. As described in Chapter 2.
Measuring SULT1E1 heterogeneous nuclear RNA (hnRNA). For measuring the
amount of SULT1E1 heterogeneous nuclear RNA (hnRNA), total RNA was isolated
using the RNeasy Mini Kit with on-column DNase I treatment, and samples of total RNA
(1.5 μg) were reverse transcribed using the High Capacity cDNA Reverse Transcription
Kit. As negative controls, equivalent amounts of total RNA were “mock reversed
transcribed” by performing the reactions in the absence of reverse transcriptase. PCR
primers were designed using Oligo Primer Analysis Software, version 7.36 (Molecular
Biology Insights, CA) and the human SULT1E1 structural gene sequence (NCBI
Reference Sequence NC_000004, 70706930-70725870 complement). The sequence
of the upper primer (5′-GCTGGTCATCCAAATCCTG-3′) was located within exon 5 and
the sequence of the lower primer (5′-CAATTTGCCTTCTACATCTGGACA-3′) was
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located within intron 5. Each PCR reaction contained 1 μl of reverse transcription
reaction as template, 25 μl of 2x SYBR Green PCR Master Mix (Applied Biosystems),
and 300 nM each of upper and lower primer in a volume of 50 μl. Samples were
incubated at 95°C for 10 min, followed by 35 cycles of 95°C for 15 sec and 60°C for 1
min, followed by a melting curve of 95°C for 15 sec, 60°C for 1 min, ramp to 95°C with
data collection every 0.3°C, and 95°C for 15 sec to ensure that a single product had
been amplified. A commercial SYBR Green-based RT-PCR assay to detect TATA box
binding protein was used for normalization (Qiagen, Valencia, CA). Following data
acquisition, Ct values were determined and data were analyzed as described above.
Control reactions containing aliquots of the mock reverse transcribed samples were
performed to determine whether any fluorescent signal was derived from contaminating
genomic DNA. To confirm amplification of the specific target fragment of expected size
(203 nt), PCR products were run on a 2% agarose gel and visualized with ethidium
bromide under ultraviolet illumination.
microRNA microarray analysis. Total RNA was prepared from different confluency
MCF10A cells using Trizol reagent (Gibco). The quality of each sample used was
checked using the RNA Nano Kit and an Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA). The following microRNA microarray procedures were
performed by the Microarray/Bioinformatics Core Facility. MicroRNA microarray
analysis was performed using the microRNA Microarray System (Agilent Technologies,
Palo Alto, CA). Each Human microRNA Microarray V2 (Cat. No. G4470B) slide contains
8 microRNA arrays. Each array consists of human and human viral microRNAs from the
Sanger miRBASE 10.1. Agilent protocol “microRNA Microarray System” v. 1.5 was
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followed during microRNA labeling and array hybridization. Samples of total RNA (100
ng) were treated with Calf Intestine Alkaline Phosphatase (GE Healthcare Bio-Sciences
Corp., Piscataway, NJ) at 37° C for 30 min. Ligation reactions were performed at 16° C
for 2 hr. The labeled microRNA samples were then purified using Micro Bio-Spin 6
columns (Bio-Rad Laboratories, Hercules, CA), dried with a speed vac, and resuspended in 18 µl of nuclease-free water. 4.5 µl of 10× GE Blocking Agent and 22.5 µl
of Agilent 2× Hi-RPM Hybridization Buffer were added, and the samples were incubated
at 100° C for 5 min and placed on ice for 5 min. Samples were immediately added to an
array in an Agilent SureHyb hybridization chamber. The hybridization chambers were
rotated at 20 rpm in a hybridization oven for 20 hr at 55° C. After hybridization, the
slides were removed from the hybridization chamber and placed in a glass slide rack in
a slide-staining dish for washing. The staining dish was placed on a magnetic stir plate,
and stirred using setting 4. The slides were washed 5 min in GE Wash Buffer 1 and 5
min in pre-warmed 37° C GE Wash Buffer 2 (Agilent Technologies). Slides were slowly
removed from wash 2 solution which allows for even drying across the slide. Slides
were then scanned using the Agilent dual laser scanner. The photomultiplier tube
settings were set at 100% and 5% for the Green channel. Tiff images were analyzed
using Agilent‟s feature extraction software.
microRNA over-expression. MCF10A cells were seeded into 24-well plates (150,000
cells/well). The following day, the standard medium was replaced with Opti-MEM
containing a premixed complex of 4 µl of the microRNA mimic (c-301032-01-0005 for
hsa-miR-100* and c-300578-05-0005 for has-miR-221). The next day, cultures (3 wells
per treatment group) were harvested for RNA. RNA samples (1.5 µg) were reverse
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transcribed using the High Capacity cDNA Reverse Transcription Kit (Applied
Biosystems, Foster City, CA). The levels of miroRNA were measured using the
following TaqMan MiroRNA assays: has-miR-100* and has-miR-221.
BrU pulse-chase labeling. The BrU procedure was performed by collaborator Dr. Mats
Ljungman at the University of Michigan. MCF10A cells grown to pre-confluency or
confluency were incubated with 2 mM BrU in conditioned medium for 30 min to label
nascent RNA. Cells were then washed 3 times in PBS and either collected directly (0 hr
time point) or chased in conditioned medium containing 20 mM uridine for 2 or 6 hr at
37°C. Total RNA was isolated using TRIzol reagent and the BrU-containing RNA was
isolated using magnetic beads (Dynabeads, Goat anti-mouse IgG, Invitrogen)
conjugated to anti-BrdU monoclonal antibody (BD Biosciences). Conversion of the
isolated BrU-containing mRNA into cDNA and real-time PCR analyses were performed
by the Microarray Core of the University of Michigan Comprehensive Cancer Center
according to protocols supplied by the manufacturer (SABiosciences, Frederick, MD).
For the real-time PCR analyses, the Cancer Drug Resistance and Metabolism real-time
RT PCR array (PAHS-004, SABiosciences) and the ABI 7900HT Sequence Detection
System from Applied Biosystems were used. The data were analyzed using RT 2 Profiler
PCR

Array

Data

Analysis

software

(http://www.sabiosciences.com/pcr/arrayanalysis.php), and the data were normalized to
the expression of 5 housekeeping genes present on the arrays. The housekeeping
genes were: β2-microglobulin, hypoxanthine phosphoribosyltransferase 1 (HPRT1),
ribosomal protein L13A, glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and βactin.
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Western blot analysis. For measurement of SULT1E1 protein content, MCF10A cells
in T75 flasks were washed with PBS and scraped into ice-cold PBS. Cells were pelleted
and homogenized by sonication in buffer (200 µl per flask) consisting of 50 mM Tris-HCl,
25 mM sucrose, 1 mM EDTA and 1x Halt protease inhibitor (Thermo Fisher Scientific,
Rockford, IL), pH 7.4. Homogenates were centrifuged at 20,000xg, 4°C for 20 min, and
supernatants were used for western blot analysis. Protein concentrations were
measured using the BCA Protein Assay (Thermo Fisher Scientific). Western blot
analysis was performed as described previously [250], using 60 µg of sample protein,
SULT1E1 antibody at a dilution of 1:2000, secondary antibody at a dilution of 1:10,000,
and enhanced chemiluminescence for immunoreactive protein detection. For western
blot analysis of AhR and ARNT, MCF10A cells in 10 cm dishes were washed twice with
PBS and then lysed using 700 μl of cold RIPA buffer (Thermo Fisher Scientific). For
SDS-PAGE, 30 µg samples of the lysates were separated on 4-20% Precise Protein
Gels (Thermo Fisher Scientific). Following transfer to polyvinylidene difluoride
membranes, the blots were developed using AhR antibody (1:500) or ARNT antibody
(1:400) and secondary antibodies at 1:10,000 dilutions. Western blots were normalized
for variations in protein loading and transfer by reincubation with a GAPDH antibody
(1:1000).
MCF10A cells stably expressing an AhR-responsive reporter. MCF10A cells were
plated into 6-well plates (700,000 cells/well). The following day, 4 µg pGudLuc
(provided by Dr. Michael Denison, University of California, Davis, CA), which contains 4
dioxin response element (DREs), and 0.65 µg pSV2neo (American Type Culture
Collection, Manassas, VA) were cotransfected into MCF10A cells using Lipofectamine
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2000. After 24 hr recovery in standard medium, transfected cells were re-plated into
medium containing 550 µg/ml G418. After two rounds of limiting dilution cloning,
individual cell clones were identified and expanded. For TCDD treatment, 50,000 or
500,000 cells were plated into 6-well plates and 48 hr after plating, cells were treated
with 0.1% DMSO or TCDD for 24 hr. After treatment, growth medium was removed and
cells were washed with PBS. Passive Lysis Buffer (Promega Corporation, Madison, WI)
was added to each well (500 µl/well) and protein concentrations were measured in
lysates using the BCA Protein Assay (Thermo Fisher). Firefly luciferase activities were
measured in aliquots containing 10 µg protein using the Dual Luciferase Reporter
Assay System (Promega Corporation, Madison, WI) and an LMAX II384 microplate
reader (Molecular Devices Corporation, Sunnyvale, CA) equipped with SoftMaxPro
software.
Conditional knockdown of AhR in MCF10A cells. A plasmid expressing a microRNAadapted shRNA targeting human AhR in a doxycycline-inducible manner (oligo ID
V2THS_132482, vector pTRIPZ) was purchased from Thermo Fisher Scientific, Open
Biosystems Products (Huntsville, AL). For transfection, 700,000 MCF10A cells were
plated into 6-well plates, and 4 µg/well plasmid was transfected into the cells using
Lipofectamine 2000 24 hr after plating. Stably-transfected cells were obtained by
incubation in culture medium containing 1 μg/ml puromycin followed by limiting dilution
cloning. To achieve AhR knockdown, cells were treated with 1 µg/ml doxycycline for 96
hr.
Transfection of a SULT1E1 5’-flanking region-luciferase reporter plasmid. A
fragment of the human SULT1E1 gene spanning from nt -7073 to +13 was amplified by
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PCR using genomic DNA from the MCF10A cells line as template, forward primer: 5′GGGGGTACCATTTGGCCTGCTATAACTGTATGCT-3′ (underscored sequence is a
KpnI site), and reverse primer: 5‟-GGGCTCGAGACTTCTGCATTTGGAATGTTTCTGG3‟ (underscored sequence is a XhoI site). The amplified fragment was ligated into the
KpnI and XhoI sites of the pGL4.17[luc2/Neo] reporter plasmid (Promega Corporation,
Madison, WI). The sequence of the SULT1E1 fragment was verified using the services
of the Applied Genomics Technology Center, Wayne State University.
For stable transfection, 700,000 MCF10A cells were plated into 6 well plates.
The following day, the cells were transfected with 4 µg of the SULT1E1 5‟-flanking
region-luciferase reporter plasmid using Lipofectamine 2000. After 24 hr recovery in
standard medium, the transfected cells were re-plated into medium containing 550
µg/ml G418 and expanded.
For transient transfections, MCF10A cells or MCF10A cells engineered for
conditional knockdown of AhR and treated with either 0.1% DMSO or 1 µg/ml
doxycycline for 96 hr were seeded into 24-well plates (150,000 cells/well). The following
day, the standard medium was replaced with Opti-MEM containing a premixed complex
of 4 µl of Lipofectamine 2000, 0.8 µg SULT1E1-luciferase reporter, and 1.25 ng pRLSV40 (Promega). The next day, cultures (3 wells per treatment group) were incubated
with fresh medium containing 0.1% DMSO, 1-3 µM MNF, or 1 µg/ml doxycycline for 24
hr. The cells were then harvested for measurement of firefly and Renilla luciferase
activities using the Dual Luciferase Reporter Assay System (Promega Corporation,
Madison, WI) and an LMAX II384 microplate reader (Molecular Devices Corporation,
Sunnyvale, CA) equipped with SoftMaxPro software.
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Computational analysis of SULT1E1 5’-flanking region for DREs and site-directed
mutagenesis. The region of the human SULT1E1 gene spanning from 10 kb upstream
of the transcription start site (as indicated by the beginning of exon 1) through exon 1
was retrieved from NCBI (nt 70,725,767 through 70,735,870 of NC_000004) and was
evaluated for the presence of DREs using MatInspector (Genomatix Software, Ann
Arbor, MI) [377]. The V$AHRR (AHR-arnt heterodimers and AhR-related factors) matrix
family was used for the search, and sites were considered to be matches if the
calculated matrix similarity was greater than the optimized matrix threshold.
A single nt change (C to A) was introduced into the core region of a DRE
predicted to be located at nt -3476 of the SULT1E1 gene within the context of the
luciferase reporter plasmid containing 7073 of the SULT1E1 5‟-flanking sequence. This
nt change has been shown to abolish the ability of the AhR•ARNT heterodimer to bind
to a DRE [378]. The nt change was introduced using the QuickChange II XL SiteDirected Mutagenesis kit (Stratagene, La Jolla, CA, USA), forward primer: 5′ACAGCAAAAACCTGGGAGTGCATGTGCACACAC-3′,

and

reverse

primer:

5′-

GTGTGTGCACATGCACTCCCAGGTTTTTGCTGT-3′. The presence of the mutation
was confirmed by sequence analysis.
Statistical analysis. As described in Chapter 2
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Results
As shown in Chapter
2, SULT1E1 mRNA is
expressed at a higher
level

in

confluent

MCF10A cells than in
pre-confluent

cells

[250]. To characterize
the

phenomenon

more fully, we first
confirmed the initial
finding

and

then

demonstrated

that

confluency-mediated
up-regulation

of

SULT1E1 expression
occurred
protein

at

the

level

(Fig.

3.1A and 3.1B). We
next

addressed

whether

the

confluency-mediated
increase

in

Fig. 3.1 SULT1E1 expression in pre-confluent and
confluent MCF10A cells. MCF10A cells were harvested at
approximately 70% and 100% confluency. A: SULT1E1
mRNA levels were measured in 6 independent
experiments using a TaqMan Gene Expression Assay. B:
SULT1E1 immunoreactive protein levels were measured in
2 independent experiments by western blot hybridization.
C: SULT1E1 hnRNA levels were measured in 6
independent experiments using a SYBR green real-time
RT-PCR assay. In panels A and C, data are expressed as
mean ± SEM, and ***p<0.001 compared to pre-confluent
cells.
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Fig. 3.2 Relative rates of SULT1E1 mRNA synthesis and degradation in preconfluent and confluent MCF10A cells. A: Confluent MCF10A cells were
subcultured and harvested at the indicated times post-plating for measurement of
SULT1E1 mRNA levels. SULT1E1 mRNA content is expressed as the log of the
fractional level measured in confluent MCF10A cells, and the first order half-life was
calculated from the least squares line. B: Bromouridine labeling was used to
measure relative rates of SULT1E1 mRNA synthesis and degradation in preconfluent and confluent MCF10A cells. The data represent the averages from two
independent experiments.
mRNA synthesis or decreased mRNA degradation. The relative levels of SULT1E1
hnRNA were measured in pre-confluent and confluent MCF10A cells as an
approximation of transcription rate. SULT1E1 hnRNA levels were significantly higher
(~8.7-fold) in confluent than in pre-confluent MCF10A cells (Fig. 3.1C). By measuring
SULT1E1 mRNA content at different times after re-plating confluent MCF10A cells, the
half-life of SULT1E1 mRNA in pre-confluent cells was estimated to be 3.4 hr (Fig. 3.2A).

65
Since microRNAs have emerged as important regulators of translation and
mRNA decay, we analyzed the expression of microRNAs in MCF10A cells at different
confluencies. Microarray analysis done by the Microarray/Bioinformatics core facility (Dr.
Alan Dombkowski, Department of Pediatrics, Children's Hospital of Michigan)
revealed that 85
microRNAs were
significantly

up-

regulated and 24
microRNAs were
down-regulated
in

confluent

relative

to

pre-

confluent
MCF10A

cells.

Computational
analysis

of

Fig. 3.3 Confluency-related decrease in miR-221 and miR100*. MCF10A cells were harvested at approximately 70% and
100% confluency. The miR-221 and miR-100* mRNA levels were
measured in 3 independent experiments using TaqMan MicroRNA
Assays. Data are expressed as mean ± sd, and *p<0.05
compared to pre-confluent cells.

the

SULT1E1 3‟-untranslated region identified 4 candidate binding sites for confluencyregulated microRNAs. The confluency-related decrease in two of these microRNAs
(miR-221 and miR-100*) corresponded with the confluency-induced increase in
SULT1E1 mRNA observed in MCF10A cells (Fig. 3.3). However, overexpression of
miR-100* or miR-221 did not suppress SULT1E1 expression in confluent MCF10A cells,
suggesting that the down-regulation of these microRNAs is not responsible for
confluency-induced SULT1E1 expression (Fig. 3.4).
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Our collaborator, Dr. Mats Ljungman of the Radiation Oncology Department,
University of Michigan, recently developed an innovative approach to measure the
relative rates of
mRNA synthesis
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Fig. 3.4 Overexpression of miR-100* or miR-221 did not
suppress SULT1E1 expression in confluent MCF10A cells.
Confluent MCF10A cells were transiently transfected with miR100* (A, B) or miR-221 (C, D). Forty-eight hours after transfection,
the cells were harvested for the measurement of microRNA (A, C)
and SULT1E1 mRNA (B, D) levels.

pre-confluent cells, while the rate of SULT1E1 mRNA degradation was 7.3-fold higher
in confluent than in pre-confluent cells (Fig. 3.2B). Taken together, these results
indicate that increased SULT1E1 mRNA stability cannot account for the increased
SULT1E1 mRNA content that is seen upon cell confluence, and that confluencemediated up-regulation is most likely due to increased transcription.
As described in the Introduction, confluence-mediated SULT1E1 up-regulation is
mirrored by down-regulation of two CYPs, CYP1A1 and CYP1S1, that are known
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transcriptional targets of AhR [365], suggesting that AhR might provide the mechanistic
link between these phenomena. Using real-time RT-PCR, we confirmed that CYP1A1
mRNA

content

was significantly
higher

in

pre-

confluent
MCF10A

cells

than in confluent
cells (Fig. 3.5A).
To

evaluate

further

whether

AhR
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varies

as

function

a
of

MCF10A
confluency,
cells
engineered

the
were
to

Fig. 3.5 Indices of AhR activity in pre-confluent and confluent
MCF10A cells. A: MCF10A cells were harvested at approximately
70% and 100% confluency, and CYP1A1 mRNA levels were
measured using a TaqMan Gene Expression Assay. Data are
expressed as mean ± SEM of 3 independent experiments. B:
MCF10A cells stably expressing an AhR-responsive luciferase
reporter were treated for 24 hr with 0.1% DMSO or 30 nM TCDD
prior to harvest at approximately 70% and 100% confluency for
luciferase determinations. Data are expressed as mean ± sd, 3
wells per treatment group. *** p<0.001 compared to pre-confluent
cells.

express firefly luciferase under the control of 4 DREs. TCDD treatment significantly
increased luciferase reporter expression, demonstrating responsiveness of the
engineered cells to AhR activation (Fig. 3.5B). Luciferase expression was significantly
(~4.5-fold) higher in pre-confluent cells than in confluent cells, supporting the
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conclusion that AhR is basally active in pre-confluent MCF10A cells but less active in
confluent cells (Fig. 3.5B).
The mRNA levels of AhR and its heterodimerization partner ARNT were ~3.0and ~1.8-fold higher, respectively, in pre-confluent than in confluent cells, and the
immunoreactive protein levels were correspondingly higher in pre-confluent cells (Fig.

Fig. 3.6 Expression of AhR and ARNT in pre-confluent and confluent MCF10A
cells. A: MCF10A cells were harvested at approximately 70% and 100% confluency.
A: AhR and ARNT mRNA levels were measured in 6 independent experiments using
TaqMan Gene Expression Assays. Data are expressed as mean ± SEM, and
***p<0.001 compared to pre-confluent cells. B: AhR and ARNT immunoreactive
protein levels were measured in 2 independent experiments by western blot
hybridization. C: BrU labeling was used to measure relative rates of AhR mRNA
synthesis and degradation in pre-confluent and confluent MCF10A cells. The data
represent the averages from two independent experiments.
3.6A and 3.6B). The higher levels of AhR mRNA and protein in pre-confluent than
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confluent cells are likely attributable to differences in mRNA stability since, using the
aforementioned bromouridine labeling technique, the rates of AhR mRNA synthesis and
degradation were determined to be 5.5- and 11.3-fold higher, respectively, in confluent
MCF10A cells than in pre-confluent cells (Fig. 3.6C).
To investigate the role of AhR in regulating SULT1E1 expression, we tested the
effects of TCDD, a potent AhR agonist, and MNF, an AhR antagonist, on CYP1A1 and

Fig. 3.7 Effects of AhR agonist and antagonist treatments on CYP1A1 and
SULT1E1 expression in MCF10A cells. A and B: Pre-confluent cultures of
MCF10A cells were treated for 24 hr with 0.1% DMSO, 30 nM TCDD, 1 µM MNF, or
TCDD and MNF in combination and harvested for measurement of CYP1A1 (A)
and SULT1E1 (B) mRNA levels. Data are expressed as mean ± SEM of triplicate
assays. C and D: Pre-confluent and confluent cultures of MCF10A cells were
treated for 24 hr with DMSO, MNF, or TCDD and harvested for measurement of
CYP1A1 (C) and SULT1E1 (D) mRNA levels. Data are expressed as mean ± SEM
of 3 independent cell culture experiments. *** P<0.001 compared to pre-confluent
cells, * P<0.05
SULT1E1 expression in MCF10A cells. In pre-confluent cells, 30 nM TCDD treatment
increased CYP1A1 mRNA content by 547-fold, while treatment with 1 µM MNF, a
concentration sufficient to abolish TCDD-mediated induction, decreased basal CYP1A1
mRNA content by >99% (Fig. 3.7A). By comparison, TCDD treatment of pre-confluent
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MCF10A cells decreased SULT1E1 mRNA content by ~57%, while MNF treatment
increased the amount of SULT1E1 mRNA by ~6.7-fold (Fig. 3.7B).
Comparing the effects of TCDD and MNF treatments in pre-confluent MCF10A
cells with those in confluent cells, TCDD-mediated CYP1A1 mRNA induction in
confluent cells was not attenuated relative to the induction seen in pre-confluent cells,

Fig. 3.8 Effect of AhR knockdown on CYP1A1 and SULT1E1 expression in preconfluent MCF10A cells. A and B: Pre-confluent MCF10A cells engineered for
conditional knockdown of AhR were treated for 96 hr with 0.1% DMSO or 1 µg/ml
doxycycline and harvested for measurement of AhR mRNA (A) and immunoreactive
protein (B) levels. In panel A, data are expressed relative to DMSO-treated cells as
mean ± SEM of 3 independent cell culture experiments. ***p<0.001 compared to
DMSO treated cells. C: Pre-confluent cells were treated for 96 hr with DMSO or
doxycycline, either alone or in combination with 1 µM MNF or 30 nM TCDD, and
harvested for measurement of CYP1A1 and SULT1E1 mRNA levels. Data are
expressed as mean ± SEM of three independent cell culture experiments.
***P<0.001, ** P<0.01, * P<0.05 compared to DMSO-treated cells.
despite the lower levels of AhR and ARNT, demonstrating the high efficacy of this AhR
agonist. As shown before, basal levels of CYP1A1 mRNA were significantly higher in
pre-confluent cells than in confluent cells. MNF treatment abolished basal CYP1A1
expression

in

both

pre-confluent

and

confluent

cells

(Fig.

3.7C).
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Fig. 3.9 Effects of MNF treatment, cell confluency, or AhR knockdown on
luciferase expression from a reporter plasmid containing 7073 of the
SULT1E1 5’-flanking sequence. A. MCF10A cells were stably transfected with the
SULT1E1-luciferase reporter plasmid and pre-confluent cells were treated with 1 to
10 µM MNF for 24 hr, after which they were harvested for measurement of firefly
luciferase activity and protein content. Each bar represents the mean ± sd of
normalized luciferase activity (3 wells per treatment group). Groups that do not
share a capital letter are significantly different from each other (p<0.001). B. Preconfluent and confluent MCF10A cells stably transfected with the SULT1E1luciferase reporter were harvested for measurement of luciferase activity as
described above (A). ***p<0.001 compared to pre-confluent cells. C. Pre-confluent
MCF10A cells were transiently transfected with the SULT1E1-luciferase reporter
containing either an intact (white bars) or mutated (black bars) predicted DRE at 3476, treated for 24 hr with 1 to 10 µM MNF, and harvested for measurement of
luciferase activities. Each bar represents the man ± sd of normalized (firefly/Renilla)
luciferase activities (3 wells per treatment group). Groups that do not share a capital
letter are significantly different from each other (p<0.05). D. Pre-confluent MCF10A
cells engineered for conditional knockdown of AhR were treated with either 0.1%
DMSO or 1 µg/ml doxycycline for 96 hr and transiently transfected with SULT1E1luciferase reporter containing intact or mutant DRE. Twenty-four hr after
transfection, cells were harvested for measurement of firefly and Renilla luciferase
activities. Groups that do not share a capital letter are significantly different from
each other (p<0.001).
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For SULT1E1, mRNA levels were significantly higher in confluent cells, and TCDD
treatment suppressed expression in both pre-confluent and confluent cells. MNF
treatment increased SULT1E1 expression in pre-confluent cells but not in confluent
cells (Fig. 3.7D), suggesting that confluency and MNF treatment increase SULT1E1
expression through a common mechanism.
As a complementary approach, MCF10A cells were engineered for conditional
(doxycycline-mediated) knockdown of AhR expression. A significant reduction of AhR
mRNA content (by ~68%), accompanied by a marked decrease in AhR immunoreactive
protein level, was achieved when the engineered cells were treated with doxycycline for
96 hr (Fig. 3.8A and 3.8B). Doxycycline treatment also caused a significant reduction in
TCDD-inducible CYP1A1 mRNA expression (Fig. 3.8C), although the reduction was
only ~30%, again indicating that this potent and efficacious AhR agonist can produce a
substantial signal even in the presence of reduced AhR levels.
When pre-confluent cells were treated for 96 hr with doxycycline, CYP1A1
mRNA levels were significantly reduced (by ~78%) while SULT1E1 mRNA levels were
significantly increased (by ~2.5-fold) (Fig. 3.8C and 3.8D). The doxycycline-mediated
increase in SULT1E1 mRNA content was comparable to the increase that was
produced when cells with intact AhR expression (i.e., not treated with doxycycline) were
treated with MNF. Also, co-treatment with doxycycline and MNF did not produce an
additive effect, indicating that the effects of doxycycline and MNF on SULT1E1
expression were mediated through the common mechanism of AhR disruption.
Computational analysis of 10Kb of the SULT1E1 5‟-flanking region identified two
candidate DREs, one at 8138 and one at 3476 nt upstream of the transcription start site.
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A fragment containing 7073 nt of the SULT1E1 5‟-flanking region was ligated into a
luciferase reporter plasmid, and this plasmid was used for stable or transient
transfection of MCF10A cells. Treatment of stably transfected, pre-confluent MCF10A
cells with MNF caused a concentration-dependent increase in reporter gene expression
(Fig. 3.9A). Also, luciferase expression was significantly higher in confluent than in preconfluent stably transfected MCF10A cells (Fig. 3.9B), indicating that the information
responsible for both confluence- and MNF-inducible SULT1E1 transcription is
contained within the 7 kb 5‟-flanking region. MNF treatment also increased luciferase
expression in pre-confluent MCF10A cells that had been transiently transfected with the
7 kb SULT1E1 reporter plasmid (Fig. 3.9C). Transfection of a SULT1E1 plasmid
containing a site-directed mutation in a core nucleotide of the DRE at -3476 did not
attenuate MNF-mediated reporter induction (Fig. 3.9C). Also, transient transfection of
the 7 kb SULT1E1 reporter plasmid into the MCF10A cells that had been engineered
for conditional AhR knockdown resulted in doxycycline-inducible reporter expression,
and mutation of the DRE did not affect this up-regulation (Fig. 3.9D). These findings
indicate that AhR inhibition/suppression-mediated SULT1E1 up-regulation is not
mediated through the DRE at -3476.
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Discussion

The impact of manipulations that alter cell-cell or cell-matrix contacts on AhR
target gene expression was first investigated by Sadek and Allen-Hoffmann [379], who
reported that the suspension of cultured human keratinocytes caused increased
expression of CYP1A1 and other AhR target genes. Further studies using Hepa1c1c7
murine hepatoma cells and variants defective in AhR signaling confirmed that cell
suspension caused activation of the AhR [380]. Subsequently, Monk et al. [381]
reported that suspension of cultured rat keratinocytes caused transient AhR activation
and CYP1A1 induction, and that co-treatment with the AhR antagonist, αnaphthoflavone, inhibited suspension-mediated CYP1A1 induction.
Cho et al. [382] then demonstrated that either suspension or monolayer culture
at low confluency caused activation of the AhR in C3H10T1/2 fibroblast clonal sub-lines.
An important conclusion from these studies was that disruption of cell-cell contact,
rather than removal from the substratum, was responsible for AhR activation. Relative
to confluent C3H10T1/2 cells, in ~70% confluent cells, there was ~4-fold activation of
an AhR-responsive reporter, which is approximately the same magnitude of CYP1A1
mRNA and pGudLuc up-regulation that we observed in confluent versus pre-confluent
MCF10A cells. In very low (5%) confluence C3H10T1/2 cells, AhR-responsive reporter
expression was activated ~13-fold, which was approximately the same magnitude that
occurred after TCDD treatment [382]. Treatments with several inhibitors of processes
involved in AhR•ARNT complex formation inhibited AhR activation whether it was
produced by TCDD treatment or loss of cell-cell contact, indicating that these stimuli
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induced AhR•ARNT complex formation through the same mechanism. However, some
treatments that interfere with the transcriptional activity of AhR•ARNT complexes
produced stimulus-dependent effects on AhR activation, suggesting that the AhR•ARNT
complexes are regulated differently after TCDD treatment and loss of cell-cell contact.
A notable difference from the findings of Monk et al. [381] was that α-naphthoflavone
treatment blocked TCDD-mediated AhR activation but not activation by loss of cell-cell
contact. Consistent with the findings of Monk et al., we found that AhR inhibitor
treatment (MNF) reduced the level of CYP1A1 expression in pre-confluent MCF10A
cells.
Most recently, Ikuta et al. [383] reported that cell density influenced the
subcellular distribution of AhR and AhR activity. AhR was predominantly nuclear in the
HaCaT human keratinocyte cell line at low confluence, both nuclear and cytoplasmic at
pre-confluence, and predominantly cytoplasmic at confluence. They also used a cellscrape model of in vitro wound healing to demonstrate that AhR became activated in
the loosely-associated cells at the border of the wound margin [383]. These
investigators hypothesized that loss of cell-cell contact activates signaling events,
possibly mediated through p38 MAPK, that increase the phosphorylation of AhR at its
nuclear export signal, which causes AhR to accumulate in the nucleus [383].
AhR function has also been linked to the cell cycle. For example, Santini et al.
[384] used centrifugal elutriation to isolate populations of TCDD-treated human
monocytic U937 cells in different phases of the cell cycle, and reported that late
G1/early S phase cells had CYP1A1 mRNA contents that were ~1.4- and 3-fold higher
than the contents of asynchronous/early G1 and G2/M cultures, respectively. These
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studies suggest that the transcriptional activation of AhR target genes by TCDD is cell
cycle-dependent and suppressed in G2/M cells. However, Cho et al. reported that
absence of cell-cell contact in low-density culture induced AhR activation was cell cycle
independent because three G1/S phase inhibitors treatment did not affect this cellconfluency-mediated AhR up-regulation [382]. Similarly, Ikuta et al. confirmed this
finding by showing that BrdUrd labeled S-phase cells had the same nuclear localization
of AhR as cells in other cell cycle phases [383].
One possible mechanism for AhR-mediated transcriptional suppression is
through the binding of the activated AhR•ARNT complex to an inhibitory DRE. Safe and
co-workers have reported that certain genes (i.e., cathepsin D, c-fos, pS2, and Hsp27)
contain pentanucleotide GCGTG sites that correspond to the core DRE motif and
function as inhibitory DREs in that the binding of liganded AhR to these sites inhibits
estrogen-mediated transcriptional activation by disrupting the binding of ER or other
transcription factors to activating sites that are located in proximity to the DREs (for
review, see [385]). Computational analysis of 10 kb of the SULT1E1 5‟-flanking region
identified two high-scoring AhR•ARNT binding sites: one at 8138 and one at 3476 nt
upstream of the transcription start site. Of note, both of these DRE sites were identified
as matches to the V$AHRARNT.03 matrix, which was compiled using, among other
sequences, the inhibitory DRE sites contained in the cathepsin D and Hsp27 genes.
Although a reporter construct containing ~7 kb of SULT1E1 5‟-flanking sequence, and
therefore the DRE at –3476, showed significant up-regulation in response to MNF
treatment, AhR knockdown, or cell confluency, site-directed mutagenesis of the DRE
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did not affect the up-regulation, suggesting that this DRE does not play a role in the
negative regulation of SULT1E1 transcription.
It is therefore probable that AhR suppresses SULT1E1 transcription by
modulating the activity of some other transcription factor. AhR has been shown to
interact physically with a variety of transcription factors or transcription factor
modulatory proteins, including nuclear receptors ERα, COUP-TFI, and ERRα1 [386];
NFκB subunits RelA and RelB [387;388]; the cell cycle regulatory protein Rb [389]; and
the apoptosis regulatory transcription factor E2F1 [390], thereby modulating their
activities either positively or negatively. AhR also engages in cross-talk interactions with
MAP kinases [390], which might modify the activities of MAP kinase-regulated
transcription factors in MCF10A cells.
Our results add to the growing number of mechanisms by which AhR modulates
estrogenic activity. Anti-estrogenic effects of AhR ligands, in particular, have been
extensively studied, and several mechanisms underlying such effects have been
reported (for review, see [385]), including (1) AhR-mediated induction of one or more
enzymes (e.g., CYP1B1) that metabolize estrogen and thereby reduce tissue active
estrogen concentrations [391]; (2) AhR-mediated induction of a transcription inhibitory
factor [392]; (3) an inhibitory action mediated by the non-productive binding of liganded
AhR to an ER target gene, which prevents ER from binding [393]; (4) association of
liganded AhR with ER, thereby disrupting a transcriptionally productive interaction
between ER and Sp1 [394]; (5) AhR -mediated reduction of cellular ER levels, by either
suppression of ER transcription [395] or acceleration of ER degradation through AhR mediated recruitment of both ER and proteosome machinery [396]; and (6) AhR-
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mediated transcriptional activation of its target genes, resulting in competition for
recruitment of the limited pool of co-activators that are shared by the Ah receptor and
ER. In this regard, ARNT is said to function as a co-activator for ER, but with selectivity
for ERβ. Thus, ARNT recruitment to AhR-target genes can reduce the transcription of
ER-target genes [397]. Concerning pro-estrogenic effects, Ohtake et al. [398] reported
that AhR ligand treatment can induce ER-mediated transcription through the formation
of an AhR•ARNT•ER complex. By this mechanism, the ligand-bound AhR•ARNT
heterodimer “hijacks” ER to enable the transcription of ER target genes in the absence
of an ER ligand [399]. In other studies, AhR ligands have been found to activate ERmediated transcriptional activity without a requirement for the AhR [400;401].
Abdelrahim et al. [401] reported that AhR ligands 3MC and PCB126 were both capable
of activating ER in MCF7 breast cancer cells, while Shipley and Waxman [400] found
that 3MC, but not PCB126 or TCDD, functioned as an ER agonist in Ishikawa uterine
cancer cells. In another study, Boverhof et al. [402] reported that TCDD treatment of
OVX mice altered the expression of numerous uterine genes that were comparably
regulated by 17α-ethynylestradiol. Co-treatment of mice with the pure anti-estrogen ICI
182,780 (ICI) inhibited both the 17α-ethynylestradiol- and the TCDD-mediated effects
on these genes [402]. In another study in mice, AhR was shown to be required for the
expression of CYP19 in the ovary, and treatment with the AhR ligand 9,10-dimethyl-1,2benzanthracene increased ovarian expression of CYP19 [403]. By demonstrating that
AhR activation suppresses expression of SULT1E1, a major estrogen-inactivating
enzyme, our study provides another mechanism by which AhR can regulate
estrogenicity.
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We suggest that AhR-mediated regulation of SULT1E1 plays an important role in
modulating estrogen mitogenicity in normal breast tissue. When the breast cells are in a
non-proliferative state, it is essential that the growth stimulatory effects of estrogen be
held to an absolute minimum. Therefore, cell-cell contact triggers molecular events that
include inhibition of AhR activity and up-regulation of SULT1E1 activity. When the
breast cells switch to a proliferative state, a lessening of cell-cell contact causes
activation of AhR activity and suppression of SULT1E1 expression, resulting in
increased active estrogen levels in the breast microenvironment.
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CHAPTER 4

TSC down-regulates SULT1E1 expression in MCF10A human breast epithelial
cells through an AhR-mediated mechanism

Introduction

Smoking, one of the leading environmental etiologic factors that is associated
with human cancers in different organs, causes diseases not only in the directly
exposed tissues of the respiratory tract but also in distant organs such as bladder and
pancreas [222;404-407]. Heart disease, which is the primary cause of death in
developed countries, and about 90% of lung cancer, which is a leading cause of
cancer-related death resulting in 1.2 million deaths annually, have been closely
associated with tobacco smoking [408-410]. In addition, some evidence supports an
association between tobacco smoking and breast cancer. For example:
Tobacco

smoke

contains

carcinogens,

including

polycyclic

aromatic

hydrocarbons (PAHs), aromatic amines, and N -nitrosamines, which have been shown
to play important roles at different stages of breast cancer development [404;409;411413]. These lipophilic carcinogens are able to pass through the alveolar membrane and
be transported to the breast through the circulatory system [414;415]. Moreover, these
fat soluble compounds can be stored in breast adipose tissue and undergo further
metabolism in situ by breast epithelial cells, which has been supported by the finding
that the breast fluid of non-lactating tobacco smokers contains mutagenic tobacco
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compounds and their metabolites, such as nicotine and its major metabolite, cotinine
[416;417]. These carcinogens and their electrophilic intermediates, such as
benzo[a]pyrene (BP), crotonaldehyde (2-butenal), and acetaldehyde, covalently bind to
nucleic acid and form carcinogen-DNA adducts, which may lead to mutation of
oncogenes and tumor suppressor genes and malignant cell transformation [418-422].
Accumulated in vitro exposure to BP, a PAH found in tobacco smoke, transforms
normal human breast epithelial cells to a precancerous stage [423].
Tobacco smoke may produce genotoxic effects in breast tissue because it
increases the prevalence and spectrum of p53 mutations and alters the expression of
genes involved in DNA repair and carcinogen metabolism, including CYP family
members,

catechol-O-methyltransferase,

acetyltransferase

glutathione-S-transferases

and

N-

[424-429].

Epidemiological studies indicate that tobacco smoking exerts anti-estrogenic
effects that manifest clinically in an early natural menopause, a lowered risk of cancer
of the endometrium, and an increased risk of some osteoporotic fractures in female
smokers. Moreover, women who smoke may have a reduced risk of uterine fibroids,
and endometriosis [430-433].

However, a recent study has indicated that a low dose

of TSC can exert estrogen-like effects both in vitro and in vivo [434]. TSC has been
demonstrated to bind and transcriptionally activate ER [435]. Cadmium, a toxic heavy
metal that occurs in nature and in high levels in cigarette smoke, has been shown to
increase the steady state levels of ER regulated genes such as pS2 and cathepsin D in
human breast cancer cells [436]. These findings indicate an estrogenic effect of TSC.
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Therefore, the role of tobacco smoke in the endocrine modulation associated with
breast cancer needs further study.
SULT1E1 is an enzyme that can decrease the hormonal activity of estrogens by
facilitating their excretion and blocking their ER-mediated activity [233-235]. Since
estrogen plays a central role in the development and progression of breast cancer
according to epidemiologic, clinical, as well as molecular and cell biology studies,
SULT1E1 is well positioned to be a main estrogen modulator and therefore closely
associated with breast cancer etiology [437;438]. Our data (see Chapter 3) suggest that
SULT1E1 expression is suppressed by AhR activation. AhR mediated gene
transcription has been shown to be activated by TSC, and tobacco smoke contains
PAHs that are known activators of the AhR [435;439]. These findings suggest that TSC
may suppress SULT1E1 expression through an AhR-mediated mechanism and thereby
alter estrogen-dependent breast cancer development. In the current study, we
investigated the effects of TSC treatment on CYP1A1, a well-characterized AhR target
gene [439], and SULT1E1 expression in the “normal” nontumorigenic human breast
epithelial cell line MCF10A.

Materials and Methods

Materials. TSC was prepared by Dr. Deepak Bhalla (College of Pharmacy and Health
Sciences, Wayne State University). The rest of the materials are as described in
Chapter 2.
Cell culture. As described in Chapter 2.
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Gene expression analysis. As described in Chapter 2
Transient transfection analysis.

As described in Chapter 2.

Statistical analysis. As described in Chapter 2.

Results

CYP1A1 has been shown to participate in metabolic activation of PAHs, a typical

Fig. 4.1 Time-dependent effects of tobacco smoke condensate (TSC)
treatment on CYP1A1 (A) and SULT1E1 (B) mRNA expression in MCF10A
cells. Pre-confluent cultures of MCF10A cells were treated for 24, 48, or 72 hr
with 0, 10 or 50 µg/ml TSC, and CYP1A1 (A) and SULT1E1 (B) mRNA levels
were measured using TaqMan Gene Expression Assays. CYP1A1 and SULT1E1
mRNA levels are expressed relative to 24-hr vehicle treated controls, and all
values represent the mean ± SD of technical replicates of the same sample.
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class of carcinogenic compounds present in tobacco smoke [404;413;435;440].
CYP1A1 expression is inducible by both PAHs and TSC through activation of the AhR
[435;439].
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Fig. 4.2 Effect of AhR antagonist treatment on TSC-mediated
regulation of CYP1A1 (A) and SULT1E1 (B). MCF10A cells
were treated for 24 hr with 0.1% DMSO; 2, 10 or 50 μg/ml TSC; or
30 nM TCDD, alone or in the presence of 1 µM of the AhR
antagonist 3‟-methoxy-4‟-nitroflavone (MNF). After treatment, the
cells were harvested for measurement of CYP1A1 (A) and
SULT1E1 (B) mRNA levels using TaqMan Gene Expression
Assays. The mRNA contents were expressed relative to the levels
measured in untreated MCF10A cells and all values represent the
mean ± SD of technical replicates of the same sample.

CYP1A1 mRNA content >50-fold, and this increase persisted for 72h (Fig. 4.1A). When
the same samples were used to examine SULT1E1 mRNA content it was found that
TSC treatment attenuated the expression of SULT1E1 in a concentration-dependent
manner at all time points tested (Fig. 4.1B). Treatment with 10 μg/ml TSC resulted in
50%, 67% and 70% decreases in SULT1E1 mRNA expression after treatment for 24 hr,
48 hr, and 72 hr, respectively (Fig. 4.1B), while 50 μg/ml TSC treatment decreased
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SULT1E1 expression by 75%, 94% and 85%, respectively, at those three treatment
times (Fig. 4.1B).
To evaluate whether AhR activation is the mechanistic reason for TSC-mediated
SULT1E1 suppression, the effects of TCDD, a potent AhR agonist, and MNF, an AhR
antagonist with little or no agonist activity [441], on CYP1A1 and SULT1E1 mRNA

with
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AHR
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in an ~100-fold
up-regulation of

(Fig. 4.2A),
while treatment
the

AhR

antagonist, MNF
(1µM),
decreased

60

D
C

40

B
20

A
0

NT

A
DMSO

B,C

C

A

0.1

0.5

1

5

10

30

TSC

CYP1A1

with

Relative Luciferase Activity

levels were tested in MCF10A cells. We first verified that treatment of MCF10A cells
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Fig. 4.3 Effect of TSC treatment on expression of an AhRresponsive reporter. MCF10A cells were transiently transfected
with pGudLuc reporter containing a 484-bp fragment from the
upstream region of the CYP1A1 gene that includes four dioxin
responsive element (DRE) [9]. Twenty-four hours post
transfection, cells were treated with nothing (NT), 0.1% DMSO, or
0.1–30 μg/ml TSC for 24 h and harvested for measurement of
luciferase activities. Each bar represents the mean ± S.D. of
normalized (firefly/Renilla) luciferase measurements (3 wells per
treatment group). Groups that do not share a capital letter are
significantly different from each other (p ≤ 0.05).

CYP1A1 mRNA level by about 99% relative to vehicle (DMSO) control (Fig. 4.2A). As
expected, TCDD treatment suppressed SULT1E1 expression by 57% and MNF
exposure induced a ~5-fold up-regulation of SULT1E1 expression (Fig. 4.2B).
Treatment with 2, 10 and 50 μg/ml TSC resulted in an induction of CYP1A1 mRNA
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levels of 35-, 169-, and 74-fold, respectively (Fig. 4.2A). By comparison, TSC treatment
decreased SULT1E1 expression by at least 44% at all of the concentrations that were
examined (Fig. 4.2B). Co-treatment with MNF abolished TCDD-mediated CYP1A1
induction and SULT1E1 suppression, but only attenuated ~30% of the 50 µg/ml TSCmediated CYP1A1 inductions and had no effect on the suppression of SULT1E1 by
TSC (Fig. 4.2).
To confirm the ability of TSC to activate the AhR in MCF10A cells, cells were
transfected with
a
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Fig. 4.4 Effect of MNF treatment on the TSC concentrationresponse curves for CYP1A1 induction and SULT1E1
suppression. MCF10A cells were treated for 24 h with 0.03–
10 μg/ml TSC in the absence or presence of 1 or 3 µM MNF. After
treatment, the cells were harvested for measurement of CYP1A1
and SULT1E1 mRNA levels using TaqMan Gene Expression
Assays. The mRNA contents were expressed relative to the levels
measured in untreated MCF10A cells and all values represent the
mean ± SD of technical replicates of the pooled sample of 3 wells
per treatment group. The fitted sigmoid curve for the data is
shown, together with the calculated EC50 or IC50 value and 95%
confidence interval (95% CI).

TSC for 24h. TSC concentrations of 0.5, 1, 5, 10, 30 µg/ml significantly enhanced
luciferase reporter expression by 3.3-, 4-, 5-, 4.9-, and 6.6-fold, respectively (Fig. 4.3),
indicating the activation of AhR. Effects of MNF treatments on the TSC concentration-
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response curves for CYP1A1 induction and SULT1E1 suppression are shown in Fig.
4.4 MNF treatment inhibited TSC-mediated CYP1A1 induction and SULT1E1
suppression and shifted the TSC concentration-responsive curves rightwards (Fig. 4.4),
suggesting a role for the AhR in TSC-mediated CYP1A1 and SULT1E1 regulation.

Discussion

It is well known that the etiology of human breast cancer is affected by complex
inherited and environmental factors [442;443]. To date, genetic studies have identified
and confirmed germ-line mutations in high-penetrance genes, such as BRCA1, BRCA2,
PTEN, and TP53; moderate-penetrance genes, such as ATM, BRIP1, CHEK2, and
PALB2; and around 20 common low-penetrance variants in 19 genes or loci that
contribute to a woman's risk of breast cancer [444]. The development of microarray
approaches enabled genome-wide analysis of breast cancer and identified numerous
genetic and epigenetic alterations involving a small number of altered signaling
pathways (PI3K, NK-κB, FGF, etc.) [445]. In addition to these genetic and well accepted
hormone-related risk factors discussed in the previous chapters, a large number of
environmental chemicals are suspected of playing a role in breast cancer [26;446;447].
For example, traffic emission, the major source of air pollution in urban areas, has been
associated with increased breast cancer risk among women living close to industrial
sites and heavy traffic in Long Island, New York [448]. Traffic emissions contain many
potential carcinogens, such as PAHs, which are also major compounds found in
tobacco smoke [449].
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Tobacco smoke has been associated with increased risk of breast cancer [450].
Various factors such as duration and intensity of smoking [451] and tobacco smoking
during first pregnancy [452] were found to influence the smoking induced risk of breast
cancer. Moreover, a direct relationship was observed between tobacco smoking and
metastasis in breast cancer [453]. However, the results of epidemiological studies to
date have not provided conclusive information about the association between tobacco
smoking and breast cancer, with some epidemiology studies reporting a positive
association [300;451;452;454-456] and some reporting a negative association
[457;458]. The inconsistencies among studies are likely due to the fact that the quantity
and duration of smoking, age at initiation of smoking, exposure to second hand smoke,
hormonal profile and gene polymorphisms of the study population are all extremely
difficult to assess accurately. Investigation of the interaction between tobacco smoke
and genes that are involved in bioactivation or detoxification processes, in endocrine
modulation, in DNA repair, and in cell cycle and apoptosis control will provide more
information about the role of environmental exposure to tobacco smoke in breast
carcinogenesis. TSC was used as a model to study the effect of tobacco smoke
exposure. Calculations by Holden et al. [459] suggest that the concentration of
condensate in the epithelial lining fluid would be 0.01-1% when one cigarette was
smoked.
AhR signaling is known to activate both phase I enzymes (most notably
CYP1A1) and phase II enzymes (mainly glutathione S-transferase Ya) in response to
tobacco smoke, which will either bioactivate procarcinogens in tobacco smoke or
sequester and detoxify reactive electrophiles [460-463]. It is therefore plausible that
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AhR-mediated processes have a measurable and biologically significant effect on the
carcinogenicity of tobacco smoke. BP, an important component of tobacco smoke,
induced tumors in wild-type mice, but not in AhR null animals [464]. The results of
Chapter 3 indicated that the expression of SULT1E1 was subjected to AhR regulation.
To investigate the inhibitory effect of TSC on SULT1E1 expression, we utilized a
chemical agonist (TCDD) and antagonist (MNF) to alter AhR signaling in MCF10A cells.
We found that TSC treatment increased the expression of CYP1A1, a wellcharacterized AhR target gene, but suppressed the expression of SULT1E1. Moreover,
the potency by which TSC suppressed SULT1E1 suppression was greater than the
potency of CYP1A1 induction. We then confirmed that TSC treatment caused AhR
activation, as indicated by significant concentration-dependent activation of a transiently
transfected AhR-responsive reporter plasmid. Co-treatment with the AhR antagonist
MNF inhibited TSC-mediated CYP1A1 induction, as indicated by MNF-dependent
rightward shifts of the TSC concentration-response curve. Treatment with MNF alone
increased SULT1E1 expression and caused rightward shifts of the TSC concentrationcurves, suggesting a role for the AhR in TSC-mediated SULT1E1 suppression. Further
studies are needed to determine whether tobacco smoke exposure causes SULT1E1
suppression in the breast in vivo, and whether such an effect plays significant role in
the development of breast cancer.
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CHAPTER 5

Knockdown of estrogen-inactivating enzyme SULT1E1 by RNAi accelerates
tumorigenesis in vivo

INTRODUCTION

Breast cancer is the leading type of cancer and the second most common cause
of cancer death in American women [1]. Breast cancer incidence rates have decreased
about 2 percent per year since the early 2000s, possibly due to the use of screening
mammography and discontinuation of postmenopausal hormone replacement therapy
(HRT) [465-470]. The latter change probably had a greater effect in that women who
took HRT to relieve menopausal symptoms had an increased risk of developing breast
cancer and there was a rapid decline in breast cancer incidence after discontinuation of
HRT [465-467]. These findings indicate that exogenous estrogen exposure influences
the development of breast cancer. Moreover, increased cumulative endogenous
exposure to estrogen resulting from early onset of menarche, later onset of
menopause, nulliparity, and late age of first pregnancy has also been associated with
increased breast cancer risk according to the results of clinical and epidemiologic
studies [22-26]. In addition to the above mentioned evidence linking breast cancer
incidence to estrogen exposure, clinical and laboratory studies have shown that
estrogen can directly stimulate the proliferation of human breast cancer cells in vitro
and drive the growth of breast tumors in vivo [29;30;471-474]. This involvement of
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estrogen in the development and progression of breast cancer provides the conceptual
basis for the potential use of estrogen modulators as treatments for breast cancer
[475;476].
Extensive biotransformation of endogenous and exogenous estrogens to
estrogen conjugates, especially to abundant circulating estrogen sulfates by SULTs,
has long been recognized as a major determinant of estrogen levels in humans
[178;232]. It has been demonstrated that normal human breast epithelial cells possess
endogenous SULT1E1 activity at physiologically significant levels [341;477]. In contrast,
many breast cancer cell lines appear to have lost the expression of SULT1E1 and
therefore lack the high affinity estrogen sulfonation pathway [249;250]. Moreover,
SULT1E1 has been shown to regulate the in situ bioavailability of estrogen in human
breast, especially in postmenopausal women [79]. In another study in which specimens
of human breast carcinoma tissues were used to examine the expression of SULT1E1,
it was found that SULT1E1 mRNA was expressed in both carcinoma and intratumoral
stromal cells [97]. It was also demonstrated that SULT1E1 immunoreactivity was
inversely correlated with tumor size or lymph node status [97]. Moreover, SULT1E1
immunoreactivity was significantly associated with a decreased risk of recurrence or
improved prognosis [97]. These studies indicate that SULT1E1 regulates the availability
of the estrogen in the breast and consequently affects cell growth. We propose that
SULT1E1 silencing might be a critical event in the transition of normal breast epithelial
cells to cancer cells by facilitating a breast microenvironment that favors increased
estrogenic stimulation.
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The MCF10A-derived lineage of human breast epithelial cell lines is a good
model to study the molecular events that occur during breast cancer neoplastic
progression. These MCF10 cell lines were all derived from a common genetic
background and the model includes the full spectrum of neoplastic progression and
incorporates aspects of both indolent preneoplastic diseases to aggressively neoplastic
breast epithelial cell growth. In the current research, we use the premalignant
MCF10AT1 cell line, which expresses SULT1E1 at a relatively high level (Chapter 2)
[250], as a model to determine the impact of SULT1E1 silencing on xenograft
progression. Understanding the function of SULT1E1, the major estrogen-inactivating
enzyme, will provide new information on in situ estrogen metabolism during human
breast cancer development. The results of this research will have implications for breast
cancer prevention and treatment.

Methods and Materials

Materials. Cell culture medium, L-glutamine, horse serum, penicillin-streptomycin
solution, sodium pyruvate, Lipofectamine 2000, Superscript II, recombinant human
SULT1E1, and anti-SULT1E1 antibody were purchased from Invitrogen Corporation
(Carlsbad, CA). EGF was purchased from BD Biosciences (San Jose, CA).
Recombinant human insulin (Novolin R) was purchased from Novo Nordisk
Pharmaceuticals, Inc. (Princeton, NJ). Doxycycline, E2, ICI 182780, cholera toxin and
hydrocortisone were purchased from Sigma-Aldrich (St. Louis, MO). The pS2 antibody
and orseradish peroxidase-conjugated goat anti-rabbit IgG was purchased from Santa
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Cruz Biotechnology (Santa Cruz, CA). FuGENE 6 Transfection Reagent was purchased
from Roche Molecular Biochemicals. ECL Plus Western Blotting Detection Reagents
and Hybond-P membranes were purchased from GE Healthcare (Piscataway, NJ). All
materials that were used to produce recombinant lentiviruses targeting human
SULT1E1 gene were purchased from Addgene (Cambridge, MA), unless otherwise
stated. Other materials were obtained from the sources indicated below.
Cell culture. The MCF10AT1 cell line was obtained from the Cell Resources Facility of
the Barbara Ann Karmanos Cancer Institute, Wayne State University and cultured in
medium as described in Chapter 2. The human HUVEC cell line was obtained from
ATCC (Manassas, VA) and maintained in F-12K medium supplemented with 0.1 mg/ml
heparin, 0.05 mg/ml endothelial cell growth supplement (ECGS) and 10% fetal bovine
serum at 37 °C with 5% CO2.
Transient transfection analysis. The p2ERE-luc reporter was constructed by ligating
a double-stranded oligonucleotide containing two vitellogenin EREs upstream of a
minimal herpes simplex virus thymidine kinase promoter, which had been preligated
into pGL3-Basic (Promega Corporation, Madison, WI). The sequences of the
oligonucleotides are: 5′-CGCGTGTCCAAAGTCAGGTCACAGTGACCTGATTCAGGTC
ACAGTGACCTGATCAAAGTTA-3′ and 5′-GATCTAACTTTGATCAGGTCACTGTGACC
TGAATCAGGTCACTGTGACCTGACTTTGGACA-3′.
MCF10AT1 cells (200,000) were seeded into 24-well plates and cultured in 0.5
ml phenol red-free DMEM/F12 Nutrient Mixture (1:1) supplemented with 10 μg/ml
insulin, 20 ng/ml EGF, 100 ng/ml cholera toxin, 0.5 μg/ml hydrocortisone, 10%
charcoal-stripped fetal bovine serum. The following day, Opti-MEM containing a
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premixed complex of 4 μl of Lipofectamine 2000, 0.8 μg p2ERE-Luc and 1.25 ng pRLSV40 (Promega) was added to each well. The following day, cultures (3 wells per group)
were incubated with phenol red-free DMEM/F12 Medium, supplemented as described
above, containing 0.1% DMSO, 0.1, 1 or 10 nM E2. After 48 hr, the cells were
harvested for measurement of firefly and Renilla luciferase activities using the Dual
Luciferase Reporter Assay System (Promega) and a Dynex model MLX Luminometer.
Heterotypic culture of MCF10AT1 and HUVEC cells. Heterotypic three dimensional
cultures were prepared based on the methods previously reported by Dr. Malathy P. V.
Shekhar [478]. In brief, 55,000 parental MCF10AT1 cells or MCF10AT1 cells that were
engineered for conditional knockdown of SULT1E1 expression were mixed with an
equal number of HUVEC cells and seeded as a single-cell suspension into 96-well
plates with a solidified layer of phenol red-free Matrigel (100 µl/well) (Collaborative
Biomedical Products, Bedford, MA). MCF10AT1 cells and HUVEC cells were prelabeled with fluorescent cationic membrane tracers, DiI and DiO (Molecular Probes, Inc.,
Eugene, Oregon), respectively, prior to coculturing. For E2 or ICI treatment, 24 hr post
plating, the co-culture system was treated with E2 or ICI alone or in combination in
charcoal stripped medium supplemented with EGF and basic fibroblast growth factor
(bFGF). Cultures were maintained at 37°C for 7 days with daily media changes, and cell
viability was measured with cellTiTer 96 cell proliferation assays according to the
manufacturer‟s directions (Promega Corp., Madison, WI). For the trypan blue exclusion
assay, 100,000 parental MCF10AT1 cells or SULT1E1 knockdown (siSULT1E1)
MCF10AT1 cells were mixed with an equal number of HUVEC cells and seeded as a
single-cell suspension into 24-well plates with solidified layer of phenol red-free Matrigel
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(400 µl/well). After the same E2 or ICI182,780 treatment for 7 days, the medium was
removed and wells were rinsed with PBS. Matrigel was digested and cells were
recovered with Cell Recovery Solution (Collaborative Biomedical Products, Bedford, MA)
according to manufacturer‟s instruction. Cells recovered were then treated with trypsin
to get single cells. The number of viable cells was determined by trypan blue solution in
a hemocytometer.
SULT1E1 conditional knockdown. To prepare a recombinant lentivirus expressing
shRNA oligonucleotides targeting SULT1E1 in a conditional manner, oligonucleotides
corresponding to the most effective shRNA that was tested,
5‟-CGCGTCGCCAGAAATTGACGCCCTTCATCTCGAGATGAAGGGCGACAATTTCTGGCTTTTTTAT-3‟
and

5‟-CGATAAAAAAGCCAGAAATTGTCGCCCTTCATCTCGAGATGAAGGGCGTCAATTTCTGGC-3‟

(Integrated DNA Technologies, INC), were ligated into the MluI and ClaI sites of
pLVTHM lentiviral plasmid, and then the fragment containing the H1 promoter and the
shRNA sequence was subcloned into the pLVCT-tTRKRAB Tet-on lentiviral plasmid
opened with MscI and FspI enzymes. This plasmid was cotransfected into 293T cells
together with psPAX2 (plasmid expressing lentiviral packaging elements) and psMD2.G
(plasmid expressing vesicular stomatitis virus envelope protein) using FuGENE 6
Transfection Reagent. Two days following transfection, medium containing lentivirus
was collected, filtered and stored at -80 °C. The viral titer was estimated by transducing
MCF10AT1 cells with several dilutions of virus and visualizing green fluorescence,
which was also expressed by the lentiviral vector. For infection, MCF10AT1 cells were
plated into 24-well plates (200,000 cells/well). After 16 hr, medium containing
recombinant lentivirus was added (the multiplicity of infection=1). Following 16h of
incubation, the cells were washed and subcultured, and doxycycline (Dox, Sigma) was
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added to half of the infected cells at a final concentration of 50 ng/ml. Five days later,
the cells were harvested and sorted by fluorescence-activated cell sorting. Then
individual clones were prepared by limiting dilution and evaluated for doxyclineinducible SULT1E1 knockdown using a TaqMan Gene Expression Assay and by
western blot analysis.
TaqMan Gene Expression assays. As described in Chapter 2.
Western blot analysis. As described in Chapter 2.
Mouse xenografts. siSULT1E1 MCF10AT1 cells were grown in T150 flasks and
harvested at 70-80% confluency. Approximately 3-4 hr before harvesting, culture
medium was replaced with fresh medium to remove dead and detached cells. Cells
were then trypsinized and live cells were counted after trypan blue staining using a
hemocytometer. Approximately 1x107 cells/site in 150–200 μl of Matrigel (Collaborative
Biomedical Products, Bedford, MA) were inoculated subcutaneously in female nude
mice aged 55-65 days (NCRNU-M-F, Taconic Farms) at 2 sites/animal using a 21gauge syringe. One week after injection, half of the mice were given doxycycline in the
drinking water (final concentration 2 mg/ml) in water bottles that were wrapped in
autoclaved alumininum foil. Fresh water containing doxycycline was prepared every
other day. Twelve weeks after injection, mice were killed and xenograft lesions were
formalin-fixed and provided to the Microscopy, Imaging & Cytometry Resources (MICR)
Core Facility (Wayne State University, School of Medicine) for histologic and
immunohistochemical analysis. These epithelial structures were graded from 0 to 5
according to the histological classification of Dawson et al. [319]. Xenografts were then
classified according to the highest grade presented in the lesion. This experiment was
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repeated 3 times and included a total of 14 mice for each group. Experimental protocols
were approved by the Institutional Animal Care and Use Committee of Wayne State
University, and guidelines relating to the ethical treatment of animals and relating to
tissue growth and burden were strictly followed.
Immunohistochemical staining (IHC). The following procedures were done by the
MICR Core Facility. Four samples from each treatment group (control and doxycyclinetreated) were used for IHC analysis. Micron sections obtained from formalin-fixed,
paraffin-embedded tissue blocks were deparaffinized, rehydrated and microwaved on
high twice for five min in 1 mM sodium citrate buffer, pH 6.0. The sections were then
washed three times in PBS and blocked with Super Block (Skytek Laboratories, Logan,
UT) for ten min. Sequential sections were then incubated with the selected primary
antibodies overnight at 4° C. The sections were then washed three times for 10 min
each in PBS and linked with the appropriate host secondary antibodies (Vector
Laboratories, Burlingame, Ca). The secondary antibodies were tagged with avidinbiotinylated

horseradish

peroxidase,

colorized

with

3‟-3‟-diaminobenzidine

and

counterstained with hematoxilin. Visualization and documentation were accomplished
with an OLYMPUS BX40 microscope supported by a DP72 CCD Camera, and
CellSens Dimension imaging software (Olympus America Inc., Center Valley, PA). The
slides were reviewed by Dr. Fred Miller (Professor, Karmanos Cancer Institute, WSU)
who confirmed the tumor grading. To assess SULT1E1 and pS2 protein levels, 4
brown-positive and blue-negative IHC stained slides from each group were counted and
measured using CellSens digital imaging software (Olympus). Three replicates per slide
were analyzed at 40×magnification. The mean percentage of brown-positive IHC stain
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was determined and statistically analyzed using Prism (GraphPad Software, San Diego,
CA).
Statistical analysis. As described in Chapter 2.

Results

It has been reported that SULT1E1 was robustly expressed in the MCF10AT1
cell line suggesting that estrogen inactivation through sulfonation is intact in MCF10AT1

line will therefore provide us with a
good

platform

to

study

the

biological role of SULT1E1 in
breast

epithelial

estrogen

metabolism. The MCF10A lineage
is a model for basal breast cancer
and

it

has

been

previously

reported

that

MCF10AT1

cells

express a negligible level of ERα
when

compared

to

the

ERα-

positive MCF7 cell line [250].
However, ERα expression levels
are sufficient in MCF10AT1 cells to
produce responses to estrogen in
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Fig. 5.1 E2-mediated activation of an
estrogen-responsive reporter gene in
MCF10AT1 cells. MCF10AT1 cells were
transiently transfected with an estrogenresponsive luciferase reporter plasmid. After
transfection, cells were treated with 0.1%
DMSO, 0.1, 1 or 10 nM E2 for 48 h. After
treatment, cells were harvested for the
measurement of luciferase activities. Each bar
represents the mean ± sd of normalized
(firefly/Renilla)
luciferase
measurements
(3 wells per treatment group) relative to the
activity measured in DMSO-treated cells.
Groups that do not share a capital letter are
significantly different from each other (p<0.05)
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vitro and, more importantly, in the MCF10AT1 mice xenograft model [317]. This
estrogen sensitive nature of MCF10AT1 cells was confirmed using an ER-responsive
reporter (Fig. 5.1). These findings make MCF10AT1 a good model to study the role of
SULT1E1 as a mediator of endogenous estrogen responses.

Fig. 5.2 Growth stimulation effects of estrogen on three-dimensional cultures
of MCF10AT1 and HUVEC cells. The heterotypic three dimensional cultures were
treated with vehicle (0.01% DMSO), the indicated concentration of E2, ICI alone, or
E2 combined with a 100-fold excess of ICI for 7 days. Cell viability was quantitated
by the trypan blue exclusion assay (A) and cell proliferation was quantitated by MTS
assay (B) on day 7 of culture. Results are from three independent experiments
performed in triplicate. Groups that do not share a capital letter are significantly
different from each other (p<0.05). In panel A, each bar represents the mean cell
number ± sd. In panel B, data are expressed relative to DMSO-treated cells as
mean ± sd.
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Fig. 5.3 SULT1E1 expression in MCF10AT1 cells engineered for conditional
knockdown of SULT1E1. MCF10AT1 cells engineered for conditional
knockdown of SULT1E1 were treated for 5 days with 0.1% DMSO or 50 ng/ml
doxycycline and harvested for measurement of SULT1E1 mRNA (A) and
immunoreactive protein (B) levels. MCT10AT1 cells engineered to express a
short-hairpin sequence targeting no known human gene (NT) were used as
control. A: SULT1E1 mRNA levels were measured in 3 independent experiments
using a TaqMan Gene Expression Assay. Groups that do not share a capital letter
are significantly different from each other (p<0.001). B: SULT1E1 immunoreactive
protein levels were measured by western blot hybridization (experiments were
repeated at least 3 times).
Breast epithelial cells cultured in monolayer lack interactions with other cell types
that are present in whole breast, such as endothelial cells. These intercellular
interactions will affect the growth as well as drug and hormone sensitivity of breast
cancer cells [479]. The in vitro three-dimensional culture system reported by Dr.
Malathy P. V. Shekhar recapitulates in vivo interaction between epithelial and
endothelial cells [478;480]. Most importantly, this system has been shown to mimic the
E2-ER induced in vivo effects associated with early angiogenesis and the proliferative
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potential of MCF10AT xenografts [478]. Therefore, the estrogen responsiveness of
MCF10AT1 cells was investigated using both MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3carbo xymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) and trypan blue exclusion
assays in heterotypic three-dimensional cultures of MCF10AT1 and HUVEC cells (Fig.

Fig. 5.4 Effects of SULT1E1 knockdown on the estrogen-regulated growth of
three-dimensional cultures of MCF10AT1 and HUVEC cells. A: MCF10AT1 and
HUVEC cells were harvested at approximately 70% confluency and SULT1E1
mRNA levels were measured in 3 independent experiments using a TaqMan Gene
Expression Assay. Data are expressed as mean ± sd, and ***p<0.001 compared to
MCF10AT1 cells. B: MCF10AT1 cells engineered for conditional knockdown of
SULT1E1 were co-cultured with HUVEC cells in three dimensional cultures and
treated with vehicle (0.01% DMSO), the indicated concentration of E2, ICI alone, or
E2 combined with a 100-fold excess of ICI for 7 days. Growth was quantitated by the
MTS assay on day 7 of culture. Data are expressed relative to DMSO-treated cells
as mean ± sd. Groups that do not share a capital letter are significantly different
from each other (p<0.05).
5.2). Many methods were used to measure cell proliferation. Trypan blue exclusion
assay is a traditional cell counting method, which is simple and inexpensive. However,
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this method is time consuming and has been reported to be inaccurate [481]. Instead,
measurement of mitochondrial metabolic rate using MTS to indirectly reflect viable cell
numbers was well accepted as an alternative method to measure cell proliferation.
However, metabolic activity may be affected by treatments which can cause significant
variation in results [482]. Therefore, both of these methods were used to accurately

Fig. 5.5 IHC staining for SULT1E1 and pS2 in xenograft lesions. MCF10AT1
cells engineered for conditional knockdown of SULT1E1 were inoculated
subcutaneously in female nude mice. Half of the mice were given doxycycline in the
drinking water. Twelve weeks post injection, mice were sacrificed and 4 lesions from
each group were analyzed by IHC. One representative IHC results from each group
was shown. Immunostaining for human SULT1E1 (brown staining) was found in
xenografts from the control group but was dramatically decreased in xenografts
from the doxycycline-treated group. In contrast, immunostaining for the estrogenresponsive gene pS2 (brown staining) was higher in xenografts from the
doxycycline-treated group (40×).
assess the effect of SULT1E1 knockdown on cell proliferation. Treatment with 1, 10
and 100 nM E2 significantly increased cell proliferation in a dose dependent manner by
at least 3-fold (Fig. 5.2A). These effects were blocked by 100 nM, 1 µM and 10 µM of
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the antiestrogen ICI, indicating that these growth stimulating effects were E2-specific
(Fig. 5.2A). The results of the MTS assay were in good agreement with those obtained
with the trypan blue exclusion assay, except that 1 µM E2 treatment was significantly
increase cell proliferation. However, E2 treatment did not produce a dose-response,
which was likely due to the saturation of the MTS assay (Fig. 5.2B).
To investigate the role of SULT1E1 in estrogen-dependent tumorigenisis,
MCF10AT1

cells

were

engineered

for

knockdown

of

SULT1E1

expression

(siSULT1E1). First, transduction-ready lentiviral particles expressing short hairpin RNA
(shRNA) (MISSION™ TRC-Hs 1.0) were used to knockdown SULT1E1 gene
expression in MCF10AT1 cells. SULT1E1 lentiviral transduction particles consisted of
five (A-E) individual constructs targeting different regions of gene sequence. MISSION®
Non-Target (NT) shRNA was used as a negative control in experiments with the
MISSION shRNA target set. NT viral vector contained four base pair mismatches within
the short hairpin sequence to any known human or mouse genes. Real-time RT-PCR
and western blot data (data not shown) revealed that different constructs had different
knockdown efficiencies. The most efficient “A” construct knocked down 92% of
SULT1E1 mRNA expression (data not shown). The other four constructs knocked down
52-85% of SULT1E1 mRNA expression. Correspondingly, western blot data showed
that SULT1E1 protein was detected in Non-targeted shRNA transduced cells but not in
the SULT1E1 shRNA transduced cells (data not shown).
This MISSIONTM lentiviral system allowed us to identify an shRNA construct for
efficient SULT1E1 knockdown quickly and easily. In this MISSION™ RNAi system, after
lentiviral particles transduction, the shRNA sequence is stably integrated into the cell's
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genome, and the shRNA is constantly expressed in the cell leading to the continuous
knockdown of SULT1E1 expression. This should elevate the level of biologically active
estrogens in the cells and increase the expression of estrogen responsive genes.
However, continuous knockdown of SULT1E1 may produce undesired effects. For
example, stable expression of SULT1E1 in MCF7 cells extensively inhibited cell growth
[247]. Therefore, a reversible, drug-regulated lentiviral Tet-on system that permits
conditional expression of SULT1E1 was employed.
The shRNA fragment of selected “A” construct was inserted into the lentiviral
vector of the Tet-on system for drug inducible production of shRNA in stably transduced
MCF10AT1 cells. In the presence of doxycycline, shRNA targeting SULT1E1 will be
expressed and SULT1E1 gene will be down-regulated [483]. This controlled shRNA

Fig. 5.6 Quantitative expression of SULT1E1 in xenograft lesions. To assess
SULT1E1 (A) and pS2 (B) protein levels, immunohistochemically stained slides
were analyzed for brown-positive and blue-negative content using CellSens digital
imaging software (Olympus). Data represent the mean percentages of brownpositive stain. ** p<0.01 ***p<0.001 (n=12). C: Four lesions from each group were
used to analyze the SULT1E1 mRNA level by TaqMan Gene Expression Assay.
Data are expressed relative to control group as mean ± sd. ***p<0.001
expression system facilitates the comparison of the behavior changes of the cells

105
developed from the same cell colony before or after doxycycline treatment. The same
genetic background of the cells make it possible to focus only on the molecular events
produced by SULT1E1 knocking down.
MCF10AT1 cells that were engineered to express a short-hairpin sequence
targeting no known human gene (NT) were used as a control (Fig. 5.3A). In the
presence of doxycycline, the short-hairpin sequence targeting SULT1E1 produced
significant knockdown of SULT1E1 mRNA content (by 53%), which was accompanied
by a marked decrease in SULT1E1 immunoreactive protein levels (Fig. 5.3). In contrast,
the NT control displayed neither SULT1E1 mRNA nor protein level changes after
doxycycline treatment (Fig. 5.3). To characterize the effect of SULT1E1 in vitro,
siSULT1E1 cells were used to repeat the MTS assay in the heterotypic culture system
(Fig. 5.4B). In order to rule out the possibility that SULT1E1 expressed by the HUVEC
cells might have contributed to estrogen metabolism, real-time RT-PCR was used to
measure SULT1E1 expression in MCF10AT1 and HUVEC cells (Fig. 5.4A). HUVEC
cells express an extremely low level of SULT1E1 mRNA compared to MCF10AT1 cells
(Fig.5.4A). SULT1E1 knockdown after doxycycline treatment did not cause a significant
change in the response to estrogen treatment, although 10 nM E2 treatment
significantly induced a 3-fold and 3.6-fold increase in cell proliferation in the vehicle
(DMSO) and doxycycline treated groups, respectively (Fig. 5.4B). These results indicate
that interaction between epithelial and endothelial cells in three-dimensional culture
system may not be enough to recapitulate the in vivo effect of SULT1E1 knockdown
due to the differences present in the microenvironment of solid tumors compared with
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cells in culture. Therefore, we analyzed the effects of SULT1E1 silencing on the
progression of siSULT1E1 MCF10AT1 xenografts.
To rule out the possibility that lentiviral transfection may cause malignant
transformation, parental MCF10AT1 cells and 3 siSULT1E1 MCF10AT1 clones were
inoculated subcutaneously in female nude mice (4 mice/ group). According to
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Fig 5.7 Effects of SULT1E1 knockdown on tumorigenicity. A: Representative
H&E stain of histological grade 2 structures (arrow) for one lesion from the control
group (10×). B: representative H&E stain of histological grade 4 structures (arrow)
for one lesion from doxycycline treated group (10×). Duct distension, rounded
lumens, and enlarged nuclei characterize the grade 4 structure. C: Summary of the
histological grades of 25 xenografts from the control group and 24 xenografts from
the doxycycline-treated group. The accumulative incidence of lesion formation was
64% and 92%, respectively, for the control and doxycycline treated group.
histological evaluation, one of the clones (S15) developed xenografts containing typical
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MCF10AT1 epithelial structures and was used in the following experiments (data not
shown). To determine whether doxycycline treatment was capable of suppressing
SULT1E1 expression in xenograft lesions, IHC and real-time RT-PCR were performed
(Fig.5.5, 5.6). In the lesions from control group, SULT1E1 was strongly stained as
brown, but in lesions from doxycycline treated group, the staining was significantly
suppressed (Fig. 5.5, Fig. 5.6A), indicating that SULT1E1 expression was knocked
down after the induction of the short-hairpin RNA by doxycycline treatment. The IHC
negative controls showed no positive staining in the lesions. The SULT1E1 down
regulation was confirmed by real-time RT-PCR analysis of four lesions from each group
(Fig. 5.6C). Functionality of the SULT1E1 knockdown on estrogen level changes was
evaluated by induction of the estrogen-responsive gene pS2 in xenograft lesions (Fig.
5.5). There was significantly more positive brown staining of pS2 in the SULT1E1
knockdown samples than there was in the control group indicating enhanced estrogen
levels in tissues with SULT1E1 knockdown (Fig. 5.5, Fig. 5.6B).Histological evaluation
(Fig. 5.7) indicated that MCF10AT1 xenografts contained epithelial structures that
resemble normal breast ducts and ductal epithelial lesions ranging from mild
hyperplasia to carcinoma in situ. These epithelial structures were graded from 0 to 5
according to the histological classification of Dawson et al. [319]. Histologic analysis
done by Dr. Fred Miller (Professor, Karmanos Cancer Institute, WSU) and MICR Core
Facility (WSU) indicated that 44% of the lesions from the control group (total of 25
lesions) lacked evidence of epithelial growth, 12% were classified as grade 1, 28%
were classified as grade 2, and 16% were classified as grade 3. By comparison, 92% of
the lesions from the doxycycline treated group (total of 24 lesions) proliferated; 12.5%
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of the lesions were classified as grade 1, 62.5% were classified as grade 2, 8.3% were
classified as grade 3, and 8.3% were classified as grade 4.

There was a dramatic

difference in the percentage of lesions in the control group and the doxycycline-treated
group xenografts containing grade 2 structures (28 versus 64%, respectively).
Moreover, only lesions from the doxycycline-treated group advanced to in situ
carcinoma (8.3% grade 4).

Discussion

The molecular changes that enable normal breast epithelial cells to transform
into invasive, metastatic cancer cells are being increasingly understood [284;303], and
gene expression profiles are being used to discriminate among different subtypes of
breast cancer. Triple-negative breast cancers (TNBC) (ER-, PR-, and HER2-negative)
have become a focus of intense research since TNBC patients have a younger age at
onset, higher tumor grade, larger tumor size, increased propensity to develop
metastases, and most importantly, they lack the three most significant therapeutic
markers for clinical management resulting in the worst outcome when compared with
other cancer subtypes [14-17;484]. The MCF10A lineage of cell lines represent a good
model to study TNBC because the malignant cancer cell lines of this lineage (e.g.,
MCF10CA1) are triple negative [314;315].
TNBC cells respond to estrogen both in vitro and in xenografts even though they
do not express ERs [326-330]. ER-negative breast cancer cell line, MDA-MB-468 and
MDA-MB-231 subclone 10A, demonstrated significant E2-stimulated growth in mouse
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xenograft models in two separate studies [485;486]. This E2-induced tumor growth was
abrogated in ER-αKO mice, indicating that ER-α mediated the effect of estrogen on
tumor growth [485]. Similarly, although MCF10AT1 cells express extremely low levels of
ERα compared to MCF-7 cells, MCF10AT1 cells exhibited E2-stimulated growth in vitro
and, more importantly, in the MCF10AT1 mice xenograft model [317]. These E2
stimulated effects may be mediated through ERβ or cross-talk between ER signaling
parthway and other signal transduction routes. In the present study, E2 treatments
significantly increased pre-neoplastic MCF10AT1 proliferation in three-dimensional
cultures (Fig. 5.2). After E2 exposure, the luciferase activity of p2ERE-Luc reporter was
significantly enhanced, indicating that ER plays an important role in MCF10AT1
estrogen responsiveness (Fig. 5.1).
Moreover, there are also clinical indications that ERα-negative tumors are
influenced by hormonal factors. For instance, OVX has been shown to reduce longterm recurrence risk and mortality of both ER-positive and ER-negative pre-menopausal
women [487]. Similarly, a large clinical study done on women carrying BRCA1 or
BRCA2 mutations demonstrated that OVX significantly reduced cancer incidence in this
high-risk population (relative risk: 80% versus 19%) [488]. Because the majority of
breast tumors that develop in women carrying BRCA1 mutations are ERα-negative
[489;490], this finding indicates that estrogen can affect the pathogenesis of ERαnegative breast cancers. Therefore, the level of SULT1E1 within breast tissues may
play a critical role in the maintenance of estrogen balance and protection of breast
tissues from the adverse effects of estrogen.
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SULT1E1 expression has been associated with a decreased risk of recurrence
as well as improved prognosis of breast cancer and its immunoreactivity was inversely
correlated with tumor size or lymph node status [97]. The genetic polymorphisms of
SULT1E1 have also been correlated with increased breast cancer risk and a disease
free survival [97;491]. Moreover, it has been demonstrated SULT1E1 may also protect
human breast by catalyzing the sulfonation of carcinogenic estrogen metabolites such
as catecholestrogens (CEs) and methoxyestrogens (MEs) [492]. Since most breast
cancer cell lines lose SULT1E1 expression [249;250], SULT1E1 silencing might be a
critical event in the transition of normal breast epithelial cells to cancer cells by
facilitating a breast microenvironment that favors increased estrogenic stimulation.
Knockdown of SULT1E1 did not significantly change estrogen stimulated
MCF10AT1 cell proliferation in three-dimensional culture in the present study. This may
be caused by the differences present in the microenvironment of solid tumors in vivo
compared with cells in culture. It has been demonstrated that specific genes may be
regulated differently in vivo vs in vitro. For example, only 11% of E2-responsive genes
identified in E2 treated T47D human breast cancer cells xenografted into in nude mice
overlapped with those E2-regulated genes found in the identical cells grown in cultures
[493]. Nude mice are valuable research tools because they do not have rejection
response. The transplanted human cells can proliferate and thereby permit in vivo study
of the human cells. Therefore, the effect of SULT1E1 silencing in pre-neoplastic
MCF10AT1 cells on tumorigenicity was studied in a nude mouse xenograft model.
SULT1E1 knockdown increased the cumulative incidence of xenograft lesion
formation (from 64% in the control group to 92% in the doxycycline-treated group),
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cellularity and histological grade of xenografts in immunodeficient mice. Moreover, the
expression of the estrogen-responsive gene pS2 was low in the control group, which is
consistent with the finding that pS2 is only expressed in ER-positive breast cancers
[494;495], but was significantly enhanced in the SULT1E1 knockdown group. These
findings indicate that SULT1E1 down-regulation activates the estrogen-responsive gene
pS2 by increasing bioactive estrogen levels and accelerates estrogen-dependent
tumorigenicity.
Most breast cancer patients are postmenopausal women who lack estrogen
produced in ovary. However, the estrogen concentrations in the breast tissue of
postmenopausal patients are similar to those of premenopausal women indicating in
situ estrogen synthesis [496]. OVX mice supplemented with exogenous estrogen
simulate the in vivo situation in the postmenopausal breast cancer patient. The effect of
SULT1E1 knockdown on estrogen-dependent tumor growth can be further studied in
OVX mice treated with or without estrogen. These studies will provide additional
information about the interplay of SULT1E1 and estrogen during breast carcinogenesis,
which might have implications for the prevention of TNBC.
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Estrogen sulfotransferase (SULT1E1) catalyzes the sulfonation of estrogens,
which limits estrogen mitogenicity. TaqMan Gene Expression assays were used to
profile the mRNA expression of estrogen receptor (ERα and ERβ) and estrogen
metabolism enzymes including cytosolic sulfotransferases (SULT1E1, SULT1A1,
SULT2A1, and SULT2B1), steroid sulfatase (STS), aromatase (CYP19), 17βhydroxysteroid dehydrogenases (17βHSD1 and 2), CYP1B1, and COMT in an
MCF10A-derived lineage cell culture model for basal-like human breast cancer
progression and in ERα-positive luminal MCF7 breast cancer cells. Low levels of ERα
and ERβ mRNA were present in MCF10A-derived cell lines. SULT1E1 mRNA was
more abundant in confluent relative to pre-confluent MCF10A cells, a non-tumorigenic
proliferative breast disease cell line. SULT1E1 was also expressed in preneoplastic
MCF10AT1 and MCF10AT1K.cl2 cells, but was markedly repressed in neoplastic
MCF10A-derived cell lines as well as in MCF7 cells. Steroid-metabolizing enzymes
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SULT1A1 and SULT2B1 were only expressed in MCF7 cells. STS and COMT were
widely detected across cell lines. Pro-estrogenic 17βHSD1 mRNA was most abundant
in neoplastic MCF10CA1a and MCF10DCIS.com cells, while 17βHSD2 mRNA was
more prominent in parental MCF10A cells. CYP1B1 mRNA was most abundant in
MCF7 cells. Treatment with the histone deacetylase inhibitor TSA induced SULT1E1
and CYP19 mRNA but suppressed CYP1B1, STS, COMT, 17βHSD1, and 17βHSD2
mRNA in MCF10A lineage cell lines. In MCF7 cells, TSA treatment suppressed ERα,
CYP1B1, STS, COMT, SULT1A1, and SULT2B1 but induced ERβ, CYP19 and
SULT2A1 mRNA expression. The results indicate that relative to the MCF7 breast
cancer cell line, key determinants of breast estrogen metabolism are differentially
regulated in the MCF10A-derived lineage model for breast cancer progression.
We recently reported that SULT1E1 expression is low in pre-confluent MCF10A
breast epithelial cells but increases when the cells become confluent. Pulse-chase
labeling experiments with bromouridine demonstrated that the confluence-mediated
increase in SULT1E1 expression was due to increased mRNA synthesis. Because AhR
activation has been shown to suppress SULT1E1 expression and loss of cell-cell
contact has been shown to activate AhR in other cell types, we tested whether the
confluency-associated changes in SULT1E1 expression were mediated by the AhR.
Relative to confluent MCF10A cells, pre-confluent cells had higher levels of CYP1A1
mRNA and greater activation of an AhR-responsive luciferase reporter, demonstrating
that AhR was active in the pre-confluent cells. AhR and ARNT mRNA and protein levels
were also higher in pre-confluent than in confluent cultures. Treatment of pre-confluent
cells with the AhR antagonist, MNF, or AhR knockdown significantly increased
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SULT1E1 expression. MCF10A cells stably transfected with a luciferase reporter
containing ~7 kb of the SULT1E1 5‟-flanking region showed both MNF- and confluenceinducible luciferase expression. Pre-confluent cells transiently transfected with the
reporter showed both MNF treatment- and AhR knockdown-mediated luciferase
induction, but mutation of a computationally predicted dioxin response element (DRE)
at nt -3476 did not attenuate these effects. These results demonstrate that SULT1E1
expression in MCF10A cells is transcriptionally regulated by confluency through a
suppressive action of the AhR, which is not mediated through a DRE at nt -3476.
Tobacco smoke has been implicated as a risk factor for breast cancer. We evaluated
the effect of TSC on expression of the estrogen-inactivating enzyme SULT1E1 in the
MCF10A human breast epithelial cell line. Because TSC contains components that are
known AhR agonists, effects of TSC treatment were compared to those of TCDD, and
effects on SULT1E1 expression were compared to those on CYP1A1. Treatment for
24-72 h with 0.05-10 µg/ml TSC produced concentration-dependent increases in
CYP1A1 mRNA content, decreases in SULT1E1 mRNA content, and increases in
expression from a transfected AhR-responsive reporter plasmid. Treatment with 10
µg/ml TSC and 30 nM TCDD produced comparable increases in CYP1A1 mRNA levels
(~300-fold) and decreases in SULT1E1 mRNA levels (~90%). Treatment with the AhR
antagonist 3'-methyl-4'-nitroflavone (MNF, at 1 uM) completely inhibited TCDD-inducible
CYP1A1 expression and partially reversed TCDD-mediated SULT1E1 suppression.
MNF also inhibited TSC-mediated CYP1A1 induction and SULT1E1 suppression as
indicated by rightward shifts of the TSC concentration-response curves. These findings
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support a role for the AhR in TSC-mediated regulation of CYP1A1 and SULT1E1
expression in human breast epithelial cells.
Despite a growing understanding of SULT1E1‟s function in steroid hormone and
drug metabolism, the role of SULT1E1 in the malignant progression of breast epithelial
cells is still unknown. In this research, MCF10AT1 cells that have preserved SULT1E1
expression and E2-ER regulative growth kinetics was used to determine the impact of
SULT1E1 expression on tumorigenicity. The effect of SULT1E1 silencing in preneoplastic MCF10AT1 cells on tumorigenicity was studied in nude mice xenografts
model. The in vivo and in vitro SULT1E1 silencing was confirmed by real-time RT-PCR,
western blot hybridization and immunohistochemistry staining. This SULT1E1
knockdown increases the cumulative incidence of xenograft lesions formation (from
64% in the control group to 92% in the doxycycline treated group), cellularity and
histological grades of xenografts in immunodeficient mice. Moreover, the expression of
estrogen responsive gene pS2 was low in control group but was significantly increased
in SULT1E1 knockdown group. These findings indicate that SULT1E1 down regulation
activate estrogen responsive gene pS2 by increasing bioactive estrogen level.
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